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The unique population structure of dog breeds, arising from their domestication 
from gray wolves and subsequent breed formation, and the similarity of their inherited 
diseases to human disorders make them an ideal comparative genetics model. Herein the 
genetic basis of three canine muscle diseases, each a model for human disease, is 
investigated using genome-wide approaches. Nemaline rod myopathy (NM) is one of the 
most common congenital myopathies in people and is characterized by rod bodies in the 
muscle fibers, muscle weakness, and reduced muscle tone. We characterized the first 
large animal model of autosomal recessive NM in a family of American bulldogs and, 
through a combination of genome-wide SNP profiling and whole exome sequencing, 
identified a nonsense mutation in NEB.  
Limb girdle muscular dystrophy (LGMD) affects the hip and shoulder muscles 
and may cause respiratory and cardiac muscle degeneration. We determined that a 
muscular dystrophy in a family of Boston terriers is a sarcoglycanopathy, a type of 
LGMD caused by mutations in one of six sarcoglycan genes, and identified a 2 bp 
deletion in SGCD through direct whole exome sequencing. Further, an unrelated Boston 
terrier having LGMD harbors a 19.4 kb deletion, omitting exons 7 and 8 of SGCD. The 
NEB and SGCD mutations are present only in the affected families. 
Juvenile dermatomyositis (JDM) is an autoimmune disease with a complex mode 
of inheritance and an environmental trigger, affecting children ages 2 to 17. In dogs, 
dermatomyositis (DMS) affects collies and Shetland sheepdogs and causes skin lesions 
and muscle weakness. We conducted genome-wide association studies in both breeds and 
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identified linkage disequilibrium with SNPs on chromosomes 10 and 31. Through whole 
genome and transcriptome sequencing, we found mutations in two novel genes, PAN2 
(chr10) and MAP3K7CL (chr31). Additionally, we identified an association with a 
haplotype of the major histocompatibility complex class II genes on chromosome 12, 
alleles of which are also associated with JDM. When variants at all three loci are 
considered together, genotypes confer low, moderate, or high risk for DMS, with 
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Dog domestication  
 The earliest domesticated species, dogs (Canis lupus familiaris) descended from 
one or more populations of gray wolves 11,000 to 35,000 years ago alongside hunter-
gatherer societies [1]. Putative domestication origins include Europe, East Asia, and the 
High Arctic. Changes in brain function, behavior, pigmentation, and diet and metabolism 
have been implicated in early dog domestication [2-6].  
 While previous studies have compared modern dogs to gray wolves to identify 
domestication genes, a recent study including village dogs, gray wolves, and three 
ancient dogs identified selective sweeps containing genes with roles in neural crest 
development and the minor spliceosome [7]. These genes may explain traits associated 
with the “domestication syndrome” that is characteristic of mammalian domesticates and 
includes floppy ears; depigmentation; and decreased body, skull, and jaw size [7,8]. 
Methylation patterns also appear to have been under selection during early domestication. 
Janowitz Koch et al. [9] identified hypermethylation of transposons in dogs compared to 
wolves, and suggest that transposons underwent expansion in dogs followed by 
epigenetic silencing. Furthermore, Banlaki et al. [10] found evidence for differential 
methylation between dogs and wolves specifically in the promoter regions of genes 
related to behavior and cognitive function. Taken together, these studies suggest that 
domestication phenotypes may be attributed to far-reaching, regulatory mechanisms 
rather than wide-spread coding variants. 
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 After the first stage of domestication from wolves, with the emergence of 
agriculture and a more sedentary human lifestyle, dogs began to appear in a range of 
body sizes and became morphologically distinct from wolves [1,11]. Archaeological 
evidence suggests that dogs were bred to pull sleds around 9000 ya in Siberia, possibly as 
early as 15,000 ya; this is the earliest evidence of selective breeding for a job [12]. More 
recently, dogs were bred for retrieving, hunting, defense, speed, and companionship; 
modern breed formation during the Victorian era included artificial selection for novelty 
or “fancy” [13,14]. This final stage of domestication yielded the majority of dog diversity 
[1,15], and today, there is more phenotype variability among dogs than in the entire 
carnivore order [1]. 
 
Dogs as a model  
 There are over 400 breeds of dog [16], and they are afflicted with approximately 
360 simple and complex naturally-occurring diseases analogous to human disease [17]. 
Dogs are superior disease models to rodents in a number of ways. As pets, dogs receive 
excellent medical care and typically have extensive health records and even family 
histories. Biological samples can be obtained from the pet population for identifying 
disease alleles, eliminating expenses associated with maintaining laboratory animals. As 
companion animals, dogs share their owners’ environment and thus are more likely than 
rodent models to be exposed to toxins and other environmental agents playing a role in 
complex disease [18]. 
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 Dogs have organ sizes similar to humans and may even be more similar 
genetically [17], which makes them particularly advantageous for gene therapy and drug 
trials. While rodent models are useful for developing gene therapies, scaling up the 
injections to human treatment poses a problem because host body weight, metabolic rate, 
and response are all factors that may not translate from a rodent model to humans [19]. 
Further, negligible contamination levels at a small-scale could be amplified and cause an 
immune response when the scale is increased for human trials [20]. Dog models are an 
ideal intermediate system to address these issues because of their more comparable size 
to humans [19], and dog models for hemophilia and inherited bleeding disorders have 
been successfully used to determine safe doses and prevent immune responses in trials 
that have translated to human treatment [21].  
 Dogs underwent two population bottlenecks: domestication from wolves and 
breed formation. The latter resulted in founder effects where a small number of 
individuals formed the basis for a breed, popular sire effects where studs who excel in 
competitions are selected to sire a disproportionately high number of puppies, and within 
breed population bottlenecks due to changes in breed standards or events like the World 
Wars, which led to near extinction of some breeds. These factors caused high genetic 
homogeneity and long stretches of linkage disequilibrium (LD) within breeds, on average 
extending 1 Mb, 100-fold greater than LD in humans [22-24]. Thus, fewer markers and 
fewer individuals are necessary to detect disease loci in dogs, tens of thousands of 
markers compared to millions needed in human studies [22,23]. However, the long LD 
can result in broad associated candidate intervals containing many genes for investigating 
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mutations. Because across-breed LD is comparable to what is observed in humans (~10 
kb) [22,23], fine-mapping studies may be successful using multiple breeds with the same 
phenotype to narrow these critical intervals. 
A consequence of selective breeding practices is that deleterious alleles become 
overrepresented in certain breeds so that about half of heritable diseases are breed-
specific, making breeds similar to geographically isolated human populations [25]. These 
alleles are passed on identical by descent within breeds and, thus, approximately two-
thirds of hereditary diseases in dogs are autosomal recessive [26]. For complex diseases 
in dogs, reduced locus heterogeneity within breeds is expected compared to human 
populations. It is likely that in dogs, a small number of genes with large effect drive 
complex diseases that in humans are governed by many loci of small effect [16]. This 
facilitates identification of associated genes; dogs may even have a recessive form of a 
human complex disease. Safra et al. [27] identified a novel gene in Weimereiners with an 
autosomal recessive neural tube defects, a disorder with complex inheritance patterns in 
humans. The gene was then found to be involved in human cases [27]. Complex disorders 
may also be studied across affected breeds to find multiple genes involved. For example, 
epilepsy manifests in different ways and certain breeds are affected with different types 
[16]. 
 
Identification of disease variants in dogs 
 The canine genome comprises 2.8 billion base pairs packaged into 38 acrocentric 
autosomes. In 2004, the dog reference genome was sequenced to 7.8x coverage in a 
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female Boxer, selected because she had low heterozygosity and provided full coverage of 
the X chromosome. A SNP map based on sequences from nine additional breeds and the 
1.5x genome of a standard poodle was also made publicly available [23,28]. Since the 
release of the reference, single nucleotide polymorphism (SNP) arrays have been 
developed for genome-wide association studies (GWAS) [29]. GWAS generate 
genotypes for SNPs distributed throughout the genome and compare allele frequencies 
between unrelated affected and healthy individuals. SNP markers proximal to the 
causative mutation will be in LD, yielding an associated region. Development of the 
Affymetrix 50K platinum panel and Illumina 22K SNP arrays enabled successful GWAS 
[30-34], including identification of a novel ichthyosis gene in Golden retrievers, which 
led investigators to mutations in the same gene in human cases [35]. 
 Today an Illumina CanineHD Bead Chip is available containing over 173,000 
SNPs, which within breeds yields between 80,000 and 120,000 informative markers, 
sufficient coverage to identify loci associated with simple Mendelian disorders and some 
complex diseases [29]. With this array, simple disorders can be mapped with very small 
numbers of cases. For example, the Safra et al. [27] study of an autosomal recessive 
neural tube defect in Weimereiners used only 4 affected dogs in the GWAS.  
 After identifying an associated region through GWAS, the best candidate gene(s) 
within the critical interval is typically selected for Sanger sequencing to identify the 
causative mutation [36-42]. This approach can be costly and time intensive, particularly if 
the candidate genes are too numerous or too large. Recently, next generation sequencing 
(NGS), or high through-put sequencing, technologies have been developed that perform 
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parallel sequencing of millions of DNA fragments; the sequences are then aligned to a 
reference genome. NGS may be used to sequence the entire (whole genome resequencing 
– WGS) or a portion of the genome (targeted-resequencing), only the exons and 
sometimes introns and regulatory regions (whole exome sequencing – WES), or the 
transcriptome (RNAsequencing) of multiple individuals concurrently. Targeted and WGS 
technologies were first used in dog studies in 2011-2012, followed by the less-expensive 
WES in 2013, and the cost of NGS continues to decline [29]. NGS technologies now 
allow for rapid variant detection and screening following GWAS [43-55].  
Recently, WGS has been utilized to identify mutations without prior mapping. 
When there are several known candidate genes for a recessive disease, WGS of a single 
case has been effective for simultaneously investigating all candidates and identifying a 
deleterious variant [56-58]. WGS has also been employed in family trio studies to filter 
variants for recessive mutations in the affected individual and obligate carrier parents 
without positional or functional candidate genes [59]. Other studies have identified 
homozygous mutations underlying recessive disease by scanning the entire genome of a 
single case and ruling out all variants present in the genomes of dogs of other breeds until 
a unique, deleterious variant is identified [60-61]. Bauer et al. [62] even identified a 
dominant de novo mutation this way for a German shepherd with ichthyosis.  
Whole exome sequencing (WES) kits provide a more cost-effective alternative to 
WGS in these simple Mendelian disorders that are likely to be caused by coding 
mutations. A handful of studies have already used this technique alone or with mapping 
to identify mutations in progressive retinal atrophy [63], glaucoma [64], and neuroaxonal 
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dystrophy [65]. Genotyping by WES was also used to conduct a GWAS for glaucoma in 
Petit Basset Griffon Vendéens [66]. Variant calling and filtering for minor allele 
frequency less than 5% in 12 cases and 12 controls yielded 61,977 SNPs, and allele 
frequency analysis revealed an association on chromosome 3. Subsequent WGS of a 
single case detected an inversion in ADAMTS17. 
 In contrast to simple recessive or dominant diseases, complex polygenic traits in 
dogs may require denser SNP arrays than the Illumina 170k and more individuals to 
detect associations in GWAS. Hayward et al. [67] conducted GWAS with 4,200 dogs and 
180,000 SNPs to identify across-breed associations with multiple complex diseases, 
including hip and elbow dysplasia and morphological traits like fur length and shedding. 
The authors suggest that increased SNP density will still be necessary for complex 
diseases and were unable to detect significant associations for several other disorders they 
investigated like lymphoma, mast cell tumor, and mitral valve degeneration.  
Associations with multigenic disease have been identified using fewer than the 
100 cases and 100 controls initially proposed by Lindblad-Toh et al. [23]. Karyadi et al. 
[68] mapped squamous cell carcinoma of the digit (SCCD) using 31 case and 34 control 
standard poodles to a region on chromosome 15. They narrowed the critical interval, 
where all affected dogs possessed at least one copy of the risk haplotype, from 813 kb to 
145 kb by investigating these SNPs in cases from two other breeds also affected with 
SCCD, Briards and Giant Schnauzers, and ultimately found a strongly associated copy 
number variant in KITLG [68]. Across-breed fine mapping approaches can be highly 
effective in the case of complex disease because the LD is much narrower compared to 
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within breeds. SCCD disproportionately affects dogs with dark coats, so after the initial 
GWAS with only dark-coated standard poodles, the authors performed a second GWAS 
comparing 24 control dark-coated to 24 light-coated control poodles. Because no 
significant associations outside of MCR1, which controls coat color and is a known skin 
cancer susceptibility locus, were detected, the authors propose that a compensatory 
mutation in this gene in light-coated dogs likely confers protection from SCCD.  
 Multibreed GWAS, potentially with denser SNP arrays, followed by whole 
genome and/or transcriptome sequencing will likely be necessary to detect variants 
underlying complex disease in dogs, especially since many will involve regulatory 
mutations rather than coding changes. 
 
Canine myopathies 
 Myopathy refers to any disease affecting the skeletal muscle and causing muscle 
weakness, without disorders of innervation or the neuromuscular junction. Two examples 
of canine myopathies and their utility as genetic models are Duchenne muscular 
dystrophy (DMD) and X-linked myotubular myopathy (XLMTM). DMD is characterized 
by the absence of dystrophin, a protein essential for muscle cell stability. Mouse and 
canine DMD (cDMD) models have been available for study for the last 30 years, but 
cDMD is more clinically and histologically similar to DMD and can replicate human 
immune response to gene therapy [19]. XLMTM was identified in a family of Labrador 
retrievers [69] found to harbor a mutation in MTM1 [70], the same gene that causes 
XLMTM in humans [71]. Affected dogs closely recapitulate the human symptoms [70], 
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and gene therapy first developed in a mouse model was successfully refined in dogs to 
correct muscle weakness [72]. In addition to muscular dystrophies and XLMTM, cases of 
nemaline rod myopathy, central core-like myopathy, myofibrillar myopathy with desmin 
storage, and centronuclear myopathy have been described in dogs [73]. Herein the 
genetic basis of three canine myopathies is described. 
Nemaline rod myopathy 
 Nemaline rod myopathy (NM) accounts for 17% of congenital myopathies in 
humans and causes reduced muscle strength and tone, involving the neck, face, and 
respiratory muscles [74]. NM is characterized by rod bodies in the skeletal muscle fiber 
and is most often caused by mutations in 10 genes encoding proteins of the sarcomere 
thin filament, which is essential for muscle contraction. The majority of cases are 
attributed to dominant mutations in ACTA1 or recessive mutations in NEB [74]. ACTA1 
encodes the primary component of the thin filament, actin, and NEB produces the giant 
protein nebulin, which stabilizes actin and allows the thin filament to reach the 
appropriate length [75]. The number of rod bodies in the muscle fiber is not correlated 
with disease severity. Of the 10 genes known to cause NM [76], mouse and/or zebrafish 
models exist for 5, including ACTA1 and NEB [77-88]; however, no large animal models 
have been described. NM has been reported in Border collie and a Schipperke, but the 
genetic basis is unknown [73]. Herein, the first molecularly characterized NM in dogs is 
described. 
Limb girdle muscular dystrophy 
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 Limb girdle muscular dystrophies (LGMD) are characterized by progressive 
deterioration of the shoulder and hip muscles and may involve the heart and respiratory 
muscles. Age of onset and severity are variable, and 31 genes have been implicated [89]. 
Autosomal recessive forms are most common with an incidence of 1 in 15,000 births 
[90]. Four of the 23 recessive subtypes of LGMD are caused by mutations in any of the 
four genes encoding subunits of the sarcoglycan complex and are termed 
“sarcoglycanopathies” [89]. Sarcoglycans function in stabilizing the cell membrane of 
muscle fibers. Mouse models exist for each form [91], and a spontaneous hamster model 
is available for δ-sarcoglycanopathy [92,93]. Gene therapy trials are already underway in 
humans for α-sarcoglycanopathy [94,95].  
Sarcoglycanopathy has been reported in a Boston terrier, Cocker Spaniel, and 
Chihuahua [73], but the cause is unknown in each case. Herein, the genetic basis of a 
sarcoglycanopathy in two Boston terriers is described; this is the first molecularly 
characterized large animal model of this disease.  
Dermatomyositis  
Juvenile dermatomyositis (JDM) is the most common inherited childhood 
inflammatory myopathy [96]. JDM causes a rash on the bony prominences (e.g. across 
the cheekbones, elbows, knees, back, and chest) [96]. Muscle weakness is common, and 
affected children describe their muscles as achy and tender and may have difficulty rising 
from a seated position or climbing stairs [97]. Like most autoimmune diseases in humans, 
females are more often affected than males [98]. JDM is strongly associated with a 
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haplotype of the human leukocyte antigen genes of the major histocompatibility complex; 
however, other genetic factors of major effect are believed to be involved [99,100]. 
Canine dermatomyositis (DMS), a model for JDM, is an autoimmune 
vasculopathy that causes alopecia and skin lesions on the bony prominences (e.g. the 
face, ears, tail tip, and across the tops of the feet) [101-103]. Severe cases also involve the 
muscles, which may result in an abnormal high-stepping gate, megaesophagus, and/or 
aspiration pneumonia [101,103]. Decreased muscle tone may be evident in the head 
musculature [101]. Clinical signs typically appear subsequent to an environmental trigger 
such as viral infection or vaccination [104]. Lesions may wax and wane throughout a 
dog’s lifetime and can be exacerbated by estrus or exposure to UV light [101,103]. Age 
of onset is variable with most dogs developing clinical signs between seven weeks and 
six months of age, but others developing signs in late adulthood [103,105]. This makes 
the disease very difficult to eliminate from the two breeds almost exclusively diagnosed 
with DMS: the collie and Shetland sheepdog. 
  
The goal of this work is to identify mutations causing two simple recessive 
diseases: NM in American bulldogs and LGMD in Boston terriers, and one complex 
disease, DMS in collies and Shetland sheepdogs. In the case of NM, SNP arrays were 
used to identify regions of the genome inherited in an autosomal recessive manner in a 
nuclear family. Cross-referencing with known candidate genes resulted in two genes of 
interest, and subsequent WES identified a nonsense mutation in NEB. Two mutations 
underlying LGMD in independent Boston terrier families were identified in a known 
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candidate gene via WES of the affected dogs and relatives. Finally, multi-breed GWAS, 
WGS, and transcriptome sequencing were all employed to identify three polymorphisms 
that in combination confer low, moderate, or high risk for DMS. 
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Abstract 
 Nemaline myopathy (NM) is a congenital muscle disorder associated with muscle 
weakness, hypotonia, and rod bodies in the skeletal muscle fibers. Mutations in 10 genes 
have been implicated in human NM, but spontaneous cases in dogs have not been 
genetically characterized. We identified a novel recessive myopathy in a family of line-
bred American bulldogs (ABDs); rod bodies in muscle biopsies established this as NM. 
Using SNP profiles from the nuclear family, we evaluated inheritance patterns at 
candidate loci and prioritized TNNT1 and NEB for further investigation. Whole exome 
sequencing of the dam, two affected littermates, and an unaffected littermate revealed a 
nonsense mutation in NEB (g.52734272 C>A, S8042X). Whole tissue gel electrophoresis 
and western blots confirmed a lack of full-length NEB in affected tissues, suggesting 
nonsense-mediated decay. The pathogenic variant was absent from 120 dogs of 24 other 
breeds and 100 unrelated ABDs, suggesting that it occurred recently and may be private 
to the family. This study presents the first molecularly characterized large animal model 
of NM, which could provide new opportunities for therapeutic approaches. 
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Introduction 
 One of the most common human congenital myopathies, accounting for 17% of 
cases, nemaline myopathy (NM) is characterized by the presence of rod bodies in the 
skeletal muscle fibers, muscle weakness, and hypotonia [1]. Proximal limb muscles, 
facial muscles, and neck flexors are most frequently affected by muscle weakness, while 
respiratory insufficiency is the primary cause of death [1]. NM is clinically 
heterogeneous and is classified into six subtypes based on severity, pattern of muscle 
weakness, and age of onset [2]. Ten genes have been implicated in NM: ACTA1, CFL2, 
KBTBD13, KLHL40, KHL41, LMOD3, NEB, TNNT1, TPM2, and TPM3 [3]. These genes 
encode proteins associated with the skeletal muscle sarcomere thin filament or Kelch 
domain proteins [4]. 
While founder mutations have been reported in Ashkenazi Jewish (NEB) [5], Old 
Order Amish (TNNT1) [6], and Turkish (TPM3) [7] populations, most NM cases involve 
de novo mutations. Among cases explained at the genetic level, most are attributed to 
recessive mutations in NEB (usually in compound heterozygosity) and dominant 
mutations in ACTA1 [1]. It is often infeasible to identify de novo mutations through 
Sanger sequencing due to numerous candidate genes and the prohibitive size of the NEB 
transcript (~26 kb, 183 exons). In recent years, next generation sequencing technologies 
that allow for simultaneous capture of candidate genes have expedited the genetic 
characterization of individual NM cases [8-11].  
Mouse models harboring mutations in ACTA1 [12-14], LMOD3 [15], KLHL40 
[16], NEB [17-19], and TPM3 [20,21] are available for study of NM subtypes, but no 
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large animal models have been described. Dog models have been instrumental in 
advancing therapeutic strategies for hereditary muscle disorders such as Duchenne 
muscular dystrophy and myotubular myopathy [22,23]. While spontaneously occurring 
forms of NM have been reported in a Border collie and a Schipperke, they were not 
characterized at the molecular level [24]. Herein, we describe a novel NM in a family of 
American bulldogs (ABDs) and determine the pathogenic variant through genome-wide 
SNP profiling and whole exome sequencing (WES).  
 
Materials & Methods 
Animals  
A five month old male ABD was evaluated at the University of Guelph 
Veterinary Teaching Hospital for non-progressive generalized muscle weakness, exercise 
intolerance, and tremors beginning at approximately two months of age. A female 
littermate had similar clinical signs, while another female littermate was reported to be 
clinically unaffected. Two other littermates could not be located. The sire and dam of the 
litter were cousins, and there was no prior history of muscle disease in the family. 
Samples from the family were collected for diagnostic procedures and submitted with 
owner consent. 
 
Histopathology and immunohistochemistry 
Biopsies from the triceps, biceps femoris, and suprascapular muscles were 
collected from both affected dogs under general inhalational anesthesia following 
electrophysiological examination. The biopsy specimens were either snap frozen in 
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isopentane (pre-cooled in liquid nitrogen) or immersion fixed in 2.5% glutaraldehyde for 
electron microscopy. Sections (8 μm) were further processed using a standard panel of 
histological and histochemical stains and reactions [25]. Similar staining and reactions 
were performed on age-matched control muscles from the tissue archives of the 
Comparative Neuromuscular Laboratory.  
 
Electron Microscopy  
 Glutaraldehyde-fixed muscle specimens were post-fixed in 1% aqueous osmium 
tetroxide prior to dehydration and embedding in araldite resin. Thick sections (1 µm) 
were stained with toluidine blue-basic fuchsin prior to light microscopic examinations, 
while thin sections (60-90 nm) were stained with uranyl acetate and lead citrate prior to 
examination in a Zeiss 10 electron microscope.  
 
DNA preparation 
DNA was extracted from muscles of both affected dogs and blood from the sire, 
dam, and unaffected littermate using the DNeasy extraction kit (Qiagen, Hilden, 
Germany). Whole blood samples from ABDs recruited for an unrelated study were 
obtained as controls [26]. DNA was isolated following the Gentra PureGene protocol 
(Qiagen). Genomic DNAs from purebred dogs of other breeds were available from our 




Illumina SNP arrays 
To date, 10 genes have been identified in human cases of NM; their canine 
counterparts lie on 10 different chromosomes. To investigate inheritance patterns at each 
gene, SNP profiles were generated for the nuclear family using the Illumina CanineHD 
BeadChip, containing 173,662 SNPs (Illumina, San Diego, CA, USA). Genotypes at 
polymorphic SNPs encompassing the candidate genes (flanking the genes within 1 Mb) 
were examined for consistency with an autosomal recessive mode of inheritance. 
 
Whole exome sequencing 
Whole exome sequencing (WES) data were generated for the dam, two affected 
siblings, and an unaffected sibling. Genomic DNA (1 µg) from each sample was 
mechanically sheared to fragments of approximately 180-250 bp (Covaris LE220, 
Woburn, MA, USA). Fragment sizes were verified for quality control (Fragment 
Analyzer, Advanced Analytical, Ankeny, IA, USA). The fragment library was hybridized 
with 120-mer biotinylated RNA baits from the SureSelect XT Canine All Exon kit 
(Agilent, Santa Clara, CA, USA), which was designed based on the UCSC CanFam2 
Ensembl and Refseq tracks as well as human protein alignments. Magnetic streptavidin 
beads were used for purification according to the manufacturer’s instructions. Library 
DNA was amplified, sequencing barcodes and adapters were added (Illumina), and 
equimolar amounts of each sample were pooled. The pool was sequenced on both lanes 
of a Rapid Flowcell on a HiSeq2500 instrument (Illumina), generating paired-end 2x100 
bp sequences, comprising on average 6 GB per sample. Sequencing data were 
 34 
demultiplexed (Illumina bcl2fastq 1.8.2), sequencing adapters were trimmed (skewer 
0.1.116), and the resulting sequence mapped to the canine genome (CanFam3.1) using 
the Burrows-Wheeler Aligner (bwa 0.7.2-r351). PCR duplicates and low-quality 
alignments were removed (samtools 0.1.18 and internal software). Variant calling was 
performed using a dual pipeline of bcftools (0.1.17) and varscan (2.3.5), and internal 
software was used to combine these files into a single variant call file (VCF) per sample. 
Reads were visualized using Integrated Genomics Viewer (IGV) [27]. Known 
variants from Ensembl dbSNP (Can Fam3.1) and from private whole genome sequence 
databases were excluded. NEB was manually screened for variants predicted to have an 
effect on the protein.  
 
Genotyping of g.52734272 
Primers for PCR were designed to capture a 489 bp region encompassing 
g.52734272 (Forward 5′-AAGTCCCAGCAGCAACATAA-3′, Reverse 5′-
GTCCAAAGTGGTCGGTCCT-3′). Products were amplified using ReddyMix master 
mix (Thermo Scientific, Waltham, MA, USA) with 0.4 µM primers, 50 ng DNA, and 
water for a total volume of 25 µL. Thermal cycling conditions were as follows: 95°C for 
5 min; 5 touchdown cycles of 95°C for 30 s, 58°C for 30 s reducing 1°C per cycle, and 
72°C for 1 min; 31 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 1 min; and a 10 min 
final elongation at 72°C. Direct sequencing was carried out with BigDye Terminator 
using an ABI 3730xl Genetic Analyzer to validate g.52734272. 
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Using the same primers and thermal cycling conditions described above, 
genotyping of g.52734272 in unrelated ABDs and other breeds was carried out through a 
restriction enzyme digest with 5 µL PCR product and either BfaI CutSmart (New 
England Biolabs, Ipswich, MA, USA) or FspBI FastDigest (Thermo Scientific) for total 
reaction volumes of 25 µL and 15 µL, respectively. BfaI (FspBI) recognizes and cleaves 
(^) the following sequence: 5′- C^TAG -3′. Digests were visualized on a 1.2% agarose 
gel, where wild type alleles are uncut (489 bp) and mutant alleles are cut once (248 bp 
and 241 bp). 
 
Gel electrophoresis and western blotting 
Frozen tissue samples were ground to a fine powder using a glass mortar and 
pestle chilled in liquid nitrogen. After 20 min of priming at -20°C, tissue was 
resuspended in a 1:1 mixture of an 8 M urea buffer (8 M urea, 2 M thiourea, 0.05 M Tris-
HCl, 0.075 M dithiothreitol, as well as 3% SDS and 0.03% bromophenol blue, pH 6.8) 
and 50% glycerol with protease inhibitors (0.04 mM E-64, 0.16 mM leupeptin, and 0.2 
mM PMSF). The solutions were mixed in a 60°C water bath for 4 min, followed by a 10 
min incubation at the same temperature. Residual debris was removed via centrifugation 
at 13000 rpm, and the supernatant was flash frozen for storage at -80°C. Initial protein 
analysis was done via a 2-7% gradient acrylamide gel. Western blot was performed on 
the samples using 0.8% agarose gels run at 15 mA per gel for 2 hours and 50 minutes. 
Following this, they were transferred onto Immobilon-P PVDF membranes (Millipore, 
Billerica, MA, USA) using a semi-dry transfer unit (Bio-Rad, Hercules, CA, USA) for 
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2.5 h at 164 mA. Membranes were briefly stained with Ponceau S to check for transferred 
proteins. Following removal of the stain, membranes were incubated with primary 
antibody at 4°C overnight. Nebulin N-terminal and C-terminal expression was quantified 
using primary antibodies specific to those regions (Myomedix #6969 and #6964 
respectively, http://www.myomedix.com). Expression was normalized to the integrated 
optical density of myoglobin heavy chain (MHC) obtained from the Ponceau S staining. 
The fluorescence of the western blots was analyzed using Odyssey Infrared Imaging 
System. Ponceau S images were analyzed with One-D scan EX (Scanalytics Inc., 
Rockville, MD, USA). 
 
Results 
Affected dogs could independently ambulate, had generalized atrophy, and the 
myopathy was relatively non-progressive (Supplemental video). Atrophy of the cervical 
and dorsal thoracic limb muscles was noted with bilateral hypertrophy of the triceps 
muscles. Serum creatine kinase (CK) activities were mildly elevated. Electromyography 
(EMG) revealed spontaneous electrical activity, consisting mainly of fibrillation 
potentials, within the proximal appendicular muscles of the thoracic limbs and the 
cervical paraspinal musculature. Motor nerve conduction velocity (MNCV) testing 
showed a mild decrease in the latency of the tibial and ulnar nerves. Respiratory 
difficulties were not present. 
A marked variability in myofiber size and generalized atrophy was present in 
muscles from the affected ABDs (Fig. 1a) compared to control muscle (Fig. 1d). The 
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predominant abnormality found in >50% of the muscle fibers from all affected muscles 
examined was rod-like inclusion bodies highlighted with the modified Gomori trichrome 
stain (Fig. 1b); these structures were not observed in control muscles (Fig. 1e) or with 
H&E staining (Fig. 1a,d). Rod-like structures tended to be centralized or peripherally 
distributed in the muscle fibers and were present in both slow twitch type 1 and fast 
twitch type 2 muscle fibers. Atrophic fibers were also of both fiber types (Fig. 1c,f). 
Numerous rods were apparent along the long axis parallel to that of the muscle filaments 
(Fig. 1g). The rods were in structural continuity with Z disks (Fig. 1h), had the same 
electron density as the Z lines of adjacent sarcomeres, and had a similar lattice pattern of 
periodic cross-striations.   
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The absence of disease in the sire and dam indicates that transmission is likely 
autosomal recessive. We hypothesized that the parents were heterozygous for a 
deleterious allele inherited identical-by-descent through a common grandparent and that 
their affected progeny were homozygous. Allelic inheritance was manually evaluated for 
28 polymorphic SNPs within or flanking the 10 candidate genes; only markers 
representing TNNT1 (CFA1) and NEB (CFA19) were consistent with a simple autosomal 
recessive pattern (Table 1).  
Figure 1. Histopathology establishes NM. Cryosections from the triceps muscle of an affected pup (a–
c) and archived control triceps muscle (d–f) were stained with H&E (a, d), modified Gomori trichrome 
(b, e) and following incubation with monoclonal antibodies against type 1 and type 2 myosin heavy 
chains (c, f). Excessive variability in myofiber size and atrophy were observed in the affected muscle 
with the H&E stain (a) compared to control muscle (d). Numerous myofibers in the affected muscle 
contained rod bodies (b, arrows) not evident in control muscle (e). Both type 1 and type 2 fibers were 
atrophic (c) with fibers of both fiber types similar in size in control muscle (f). Bar 50 µm for 
images a–f. By electron microscopy, numerous electron dense rods were apparent along the long axis 
parallel to that of the muscle fiber (g). The rods were in structural continuity with Z disks (h), had the 
same electron density as the Z lines of adjacent sarcomeres, and had a similar lattice pattern of periodic 









105264488 AG AG GG GG AG 
105432142 GG AG AG AG GG 
105598975 GG CG CG CG GG 
106497529 AG AG AA AA AG 
ACTA1 
(4) 
12713391 AG AA AG AG AA 
12875911 AG AA AG AG AA 
TPM3 
(7) 
45997866 CC AC CC CC CC 
46022207* AT AA AA AT AT 
46034262* AC AA AA AC AC 
46049585* AG AG AA AG AG 
46303991 CC AC CC CC CC 
CFL2 
(8) 
16507437 CC AC CC AC CC 
16587360 GG AG GG AG GG 
TPM2 
(11) 
55241525* AC CC CC AC AC 
55248320* AA AG AA AG AA 
NEB 
(19) 
55761948* GG AG GG GG GG 
55777049* GG AG GG GG GG 
55824838* AG AG AA AA AG 
LMOD3 
(20) 
25536336 AG AA AA AA AG 
25605665 AA GG AG AG AG 
25625642 AG AA AA AA AG 
KLHL40 
(23) 
14709678 AC AA AC AC AC 
14867876 AG GG AG AG AG 
KBTBD13 
(30) 
32370798 AG GG GG GG AG 
32443189 AG GG GG GG AG 
32458624 AC AA AA AA AC 
KLHL41 
(36) 
17244342 AG AA AA AA AG 




      
    
Table 1. Genotypes for the nuclear family are reported for polymorphic SNPs (CanFam2) 
representing each of the 10 candidate genes. When possible, SNPs lying within the gene are used 
(asterisks); otherwise, the most proximal flanking SNPs are reported. When present, flanking SNPs 
(within 1 Mb) for which the affected dogs are homozygous are also shown. SNPs fitting a recessive 
pattern of inheritance are highlighted in bold 
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We conducted WES of four family members because of the large size of NEB. 
Across the samples, exome coverage, mappable reads, yields, and mean quality scores 
averaged 30X, 59 million, 6 Mb, and 37.1, respectively. VCFs were used to filter variants 
within the two candidate genes for those fitting recessive transmission (homozygous 
alternate in both affected dogs, heterozygous in the dam, and heterozygous or 
homozygous reference in the unaffected sibling). This step eliminated all 11 variants 
identified within TNNT1 and 343 variants in NEB. Thirty-six remaining variants in NEB 
were filtered to remove common polymorphisms, non-coding variants, and non-
damaging variants (Fig. 2a). Only one overtly deleterious variant was identified in NEB, a 
nonsense mutation g.52734272 C>A, corresponding to human exon 169 (S8042X; 
NP_001258137.1). In addition, we confirmed that no variants in the other eight candidate 
genes segregated with the phenotype. The NEB nonsense mutation was verified by 
Sanger sequencing (Fig. 2b) and was absent in 100 unrelated ABDs and five dogs each 
from 24 other breeds, determined by restriction digest genotyping.  
Protein analysis of the triceps biopsies from the affected dogs suggested a loss of 
NEB, which was then confirmed via western blotting (Fig. 3a,b). These values were 
quantified, revealing NEB expression at 0.3% and 16.2% of their wild-type counterparts 






Figure 2. Filtering of NEB variants reveals S8042X. (a) Filtering parameters are shown to the left 
with the number of rejected variants to the right. Total variants prior to each filtering parameter are 
shown above the arrows, beginning with the total number of variants. (b) Chromatograms from Sanger 
sequencing show the wild-type and mutant alleles. 
Figure 3. Nebulin is drastically reduced in skeletal muscles with S8042X. (a) Protein analysis on a 
2-7% gradient acrylamide gel reveals a clear loss of nebulin in muscles from affected dogs compared to 
healthy controls. (b) Western blots for the same samples using antibodies to nebulin’s N- and C- 
terminus. (c) and (d) Average quantification (CTRL 1 and CTRL 2; AFF 1 and AFF 2) of western blots, 
indicating a severe loss of nebulin protein in affected dogs. 
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Discussion 
Histological and clinical findings from the affected ABDs are consistent with 
primary NM. While the nemaline rod bodies are hallmarks of the disease, these 
morphological features provide little indication of subtype or genetic etiology. The most 
common of the six subtypes is typical congenital NM, which is most often attributed to 
mutations in NEB [1,2]. The clinical presentation of independent ambulation and 
relatively non-progressive muscle weakness at two months of age in the ABDs is 
consistent with typical congenital NM [28]. 
We used a bipartite approach to uncover a nonsense mutation in NEB causing 
ABD NM. To refine the list of 10 known candidate genes, we generated genome-wide 
SNP profiles. Affected dogs inherited identical SNP haplotypes spanning TNNT1 and 
NEB; therefore, these genes were prioritized for further study. Together, they comprise 
nearly 200 exons, rendering Sanger sequencing impractical. Instead, we utilized WES, an 
approach that provides high exon read coverage and the data to parse the rest of the 
exome if no mutations are found in candidate genes. 
NEB, or nebulin, is a giant protein (600-900 kDa) that stabilizes the actin thin 
filament of skeletal muscle sarcomeres and is critical for proper thin filament formation 
and muscle contraction [29]. NEB mutations account for up to 50% of molecularly 
characterized NM cases [30]; most are truncating [31]. NEB has a multitude of isoforms 
achieved primarily through alternative splicing of three sets of exons (63-66, 143-144, 
and 167-177); truncating NEB mutations are frequently found in the latter set. In general, 
homozygous truncating mutations may be less tolerated in ubiquitously expressed exons 
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[31]. Consistent with these trends observed in human myopathies, S8042X lies in the 
alternatively spliced exons 167-177.  
We elected to investigate NEB protein levels, rather than transcript presence, in 
cases and controls due to limited tissue quantities. Protein gels show little banding in the 
NEB region, a finding consistent with the absence of protein detected with the N-
terminus anti-nebulin antibody. The C-terminus antibody showed a low level of protein 
(~16% of the levels in the control tissues) but with a mobility slightly larger than that of 
NEB in the control samples. It is possible that this is a unique splice isoform of nebulin 
that has low abundance and excludes the N-terminus. Alternatively, the C-terminus 
antibody may be cross-reacting with another protein similar in size or a degradation 
product of a larger protein. We consider the cross-reactivity hypothesis more likely 
because we have detected titin degradation products of a size similar to NEB that cross-
react with NEB C-terminus antibodies in previous work. Regardless, our data suggest that 
S8042X results in very low levels of NEB, probably due to nonsense-mediated decay. 
The inability to successfully express normal levels of full-length nebulin likely underlies 
the pathology of the affected ABDs.  
While we report the first mutation causing NM in dogs, this is not the first 
pathogenic variant described in canine NEB. Ahram et al. [32] identified NEB missense 
mutations associated with primary angle-closure glaucoma (PACG) in Basset hounds. 
Interestingly, affected Basset hounds display no clinical signs of NM [32]. Ocular 
abnormalities were not identified in either of the ABDs with NM, nor are they associated 
with human NM attributed to NEB.  
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The recent development of WES enrichment kits for canines [33,34] will facilitate 
faster discovery of pathogenic variants, particularly when candidate genes are sizable or 
numerous. Massive parallel sequencing of several exome libraries in a single hi-seq lane 
is an economical approach for sequencing of multiple individuals, relative to whole 
genome resequencing, and permits simultaneous identification and filtering of variants. 
To date, this report is one of few to use WES in a nuclear family to identify a pathogenic 
variant in dogs [32,35]. Rather than requiring the widespread distribution of the ABD 
mutation throughout the population in order to gather sufficient cases for analysis with 
traditional methods, WES allowed us to detect the mutation directly in the two probands.  
Although no carriers were found in a survey of unrelated ABDs (extended family 
members were unavailable for study), a genetic test now exists for S8042X should NM 
arise again in the breed. The identification of carriers holds potential for the development 
of a colony for testing of therapeutic approaches for humans. 
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Limb-girdle muscular dystrophies (LGMDs) are a heterogeneous group of inherited 
autosomal myopathies that preferentially affect voluntary muscles of the shoulders and 
hips. LGMD has been clinically described in several breeds of dogs, but the responsible 
mutation(s) are unknown. The clinical presentation in dogs is characterized by marked 
muscle weakness and atrophy in the shoulder and hips during puppyhood.  
Methods 
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Following clinical evaluation, the identification of the dystrophic histological phenotype 
on muscle histology, and demonstration of the absence of sarcoglycan-sarcospan 
complex by immunostaining, whole exome sequencing was performed on five Boston 
terriers: one affected dog and three family members, and one unrelated affected dog.  
Results 
Within sarcoglycan-δ (SGCD), a two base pair deletion segregating with LGMD in the 
family was discovered, and a deletion encompassing exons 7 and 8 was found in the 
unrelated dog. Both mutations are predicted to cause an absence of SGCD protein, 
confirmed by immunohistochemistry. The mutations are private to each family.  
Conclusions 
Here we describe the first cases of canine LGMD characterized at the molecular level 
with the classification of LGMD2F.   
Keywords 
muscle, myopathy, sarcoglycanopathy, dog, LGMD 
 
Background 
Limb-girdle muscular dystrophies (LGMDs) are a heterogeneous group of 
Mendelian disorders affecting voluntary muscles of the shoulders and hips [1]. While 
proximal limb muscles are primarily affected in LGMD, other muscles may degenerate as 
well, such as the heart and respiratory muscles [1]. Sarcoglycanopathies are a subset of 
severe, recessive LGMDs (LGMD2C-F) that present in early childhood [2]. There are six 
known sarcoglycan genes (SGCA, SGCB, SGCD, SGCG, SGCE, and SGCZ); the first 
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four encode single-pass transmembrane glycoproteins (α-, β-, δ-, γ-sarcoglycans) and, 
along with sarcospan, make up the tetrameric sarcoglycan-sarcospan complex (SGC). As 
part of the dystrophin-glycoprotein complex, the SGC is critical for maintaining 
sarcolemmal stability [3]. Mutations in SGCA, SGCB, SGCD, or SGCG can result in non-
assembly of the SGC and, therefore, the absence of all four sarcoglycans from muscle of 
affected patients [3,4]. There are only a handful of low frequency founder alleles in 
human populations responsible for sarcoglycanopathies [5]; thus they are most commonly 
caused by mutations in compound heterozygosity [6]. 
In the domestic dog (Canis familiaris), selective breeding practices encourage 
pairing of recessive alleles inherited identical by descent (IBD). Accordingly, dogs have 
an abundance of recessive disorders [7], including muscular dystrophies [8,9]. Most 
canine muscular dystrophies are associated with dystrophin deficiency, and founder 
alleles have been identified in several breeds [10,11]. Recently, two independent 
mutations causing dystrophinopathy were described in Cavalier King Charles spaniels 
[12,13]. 
The first report of LGMD associated with sarcoglycan deficiency in dogs 
involved three breeds: Chihuahua, Cocker spaniel, and a seven-month-old male Boston 
terrier from Colorado (Case 1), but mutations were not identified [8]. Four years later, 
sarcoglycanopathy was described again in an unrelated four-month-old male Boston 
terrier from Iowa [14] (Case 2). All dogs affected with sarcoglycanopathy had a clinical 
dystrophic phenotype including muscle wasting, gait abnormalities, enlarged tongue, 
dysphagia, and extremely elevated serum creatine kinase (CK) activities [8,14]. 
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Pathologic features were consistent with dystrophy, having myofiber degeneration, 
regeneration, and calcific deposits [8,14]. Affected dogs lacked muscle α-, β-, and γ-
sarcoglycans, confirmed by both western blotting and immunohistochemistry [8,14]. At 
the time of evaluation, an antibody reactive with canine δ-sarcoglycan was unavailable.  
Here, we describe a sarcoglycanopathy in a third family of Boston terriers from 
Arkansas in which two puppies (Cases 3 and 4) from the same kennel but different litters 
displayed clinical signs of LGMD, pathological changes consistent with a dystrophic 
phenotype and immunohistochemical confirmation of absent or decreased sarcoglycans. 
To identify the genetic basis for LGMD in the Boston terrier breed, we performed whole 
exome sequencing (WES) of Cases 1 and 3 and related dogs. Evaluation of the 
sarcoglycan genes revealed, to our surprise, two private deletions in SGCD: a 2 bp 
deletion in exon 6 and a 19.4 kb deletion encompassing exons 7 and 8. Both cause a lack 
of SGCD, resulting in LGMD2F. 
 
Materials and Methods 
Animals  
Clinical details of Case 1 were previously published [8]. Biological samples from 
Case 2 were not available. Female Boston terriers, ages 12 months and 5 months, and 
from the same breeder in Arkansas (Cases 3 and 4), were evaluated for a chronic history 
of progressive dysphagia, lack of appetite, drooling, muscle wasting, and greatly enlarged 
tongues. Both dogs were examined by the same veterinarian in a clinical setting. 
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 DNA was extracted from diagnostic muscle biopsies of Cases 1 and 3 and whole 
blood of unaffected relatives of Cases 3 and 4 using the DNeasy extraction kit (Qiagen, 
Hilden, Germany). Muscle for isolation of DNA was unavailable from Case 4. Whole 
blood samples or buccal swabs from unrelated, healthy Boston terriers were recruited, 
and DNA was isolated following the Gentra PureGene protocol (Qiagen, Hilden, 
Germany) or the MagJet Genomic DNA purification kit (ThermoFisher Scientific, 
Waltham, USA). Genomic DNAs from unaffected dogs from multiple breeds were 
available from DNA archives at Clemson University and CAG GmbH.   
 The dogs in this study were examined and tissues collected in a clinical practice 
setting with the written consent of their owners. Studies on tissue biopsies and blood 
samples were approved by the Institutional Animal Care and Use Committees (IACUC) 
of Clemson University, the University of California San Diego, the University of Iowa, 
and the Animal Experiment Board in Finland (ESAVI/7482/04.10.07/2015), as well as 
the Baden-Württemberg veterinary office at the Landratsamt Tübingen Abt. 32: 
Veterinärwesen und Lebensmittelüberwachung, Tübingen, Germany (Registriernummer: 
DE 08 416 1038 21). 
 
Histology and Immunofluorescence 
Muscle specimens from Case 1 were previously obtained as biopsies and archived 
at -80ºC at the Comparative Neuromuscular Laboratory, University of California San 
Diego (CNL). Specimens from limb muscles, heart, and tongue of Cases 3 and 4 were 
collected by a veterinarian following humane euthanasia at 1 year of age. Muscles were 
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either refrigerated or immersion fixed in buffered formalin and shipped to the CNL. 
Cryosections from all muscle specimens were processed by a standard panel of 
histochemical stains and reactions [15]. 
Antibodies used for immunofluorescence were rabbit antibodies R98 anti- α-
sarcoglycan  [16], R214 anti- δ-sarcoglycan [17], IIH6 anti- α-dystroglycan [18], R256 
anti-sarcospan [19]; mouse antibodies 5B1 anti- β-sarcoglycan [19], 21B5 anti- γ-
sarcoglycan [19], AP83 anti- β-dystroglycan  [18], anti-dystrophin (AbCam), anti-
collagenVI (Fitzgerald), and anti-caveolin 3 (BD Transduction Laboratories); rat anti-
perlecan (NeoMarkers).  
 For secondary immunofluorescence, tissues were blocked with 10% goat serum 
in phosphate-buffered saline, incubated in primary antibody overnight, washed, incubated 
in Alexa Fluor 488, 594, or 647-conjugated anti- rat, rabbit, or mouse antibodies (Life 
Technologies), respectively, and mounted using ProLong Gold mounting media (Life 
Technologies). For α-dystroglycan, sarcospan, δ-sarcoglycan, and γ-sarcoglycan staining, 
tissues were fixed in 2% paraformaldehyde, followed by incubations in 100 mM glycine 
and 0.05% SDS prior to processing as described above. Images were acquired using a 
VS120-S5-FL slide scanner microscope (Olympus) with VS-ASW software. 
 
Parentage Testing 
The Canine Genotypes Panel 1.1 (ThermoFisher Scientific) was used to verify 
parentage of the experimental dogs. Samples were amplified according to manufacturer’s 
instructions and separated and detected on an ABI 3730XL (Applied Biosystems, 
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ThermoFisher Scientific). GeneMarker (Softgenetics, State College, PA, USA) was used 
to assign peaks and determine genotypes according to ISAG nomenclature. 
 
Whole exome sequencing 
DNA from five Boston terriers (Case 1, Case 3, and three unaffected relatives of 
Cases 3 and 4) was used for WES performed at CeGaT GmbH (Tübingen, Germany). 
Genomic DNA (1 µg) from each sample was mechanically sheared to approximately 
180–250 bp fragments using a Covaris LE220 Ultrasonicator (Woburn, MA, USA). 
Fragment sizes were assessed for quality control purposes (Fragment Analyzer, 
Advanced Analytical Technologics Inc.), and the Agilent SureSelect XT Canine All Exon 
kit (Santa Clara, CA, USA) supplied the 120-mer biotinylated RNA bases with which the 
fragment library was hybridized. Magnetic streptavidin beads were used for purification 
according to the manufacturer’s protocol (Agilent). After amplification of library DNA, 
adaptors and barcodes for sequencing were added (Illumina), and equimolar amounts of 
each sample were pooled. Both lanes of a Rapid Flowcell were used to sequence the pool 
on an Illumina HiSeq2500, generating 2x100bp paired-end sequences, resulting in 
approximately 6 GB per sample. Illumina bcl2fastq 1.8.2 was used to demultiplex 
sequencing data, skewer 0.1.116 was used to trim sequencing adapters, and the Burrows-
Wheeler Aligner (bwa 0.7.2-r351) was used to map the sequences to the canine genome 
(CanFam3.1). Samtools 0.1.18 and internal software were used to remove PCR duplicates 
and low-quality alignments. bcftools (0.1.17) and varscan (2.3.5) and internal software 
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were used to call variants, and a single Variant Call Format (VCF) file was generated for 
each sample using internal software.   
IGV [20]  and Genome Browse (Golden Helix [21,22] Inc., USA) were used to 
visualize data, and the Ensembl dbSNP (Can Fam3.1 version) and whole genome 
sequences (Clemson) were used to exclude variants.  
 
Variant characterization and genotyping 
2 bp deletion 
The 2 bp deletion identified in Case 3 was verified by Sanger sequencing, using 
primers designed to amplify SGCD exon 6 (Additional File 1: Table S1). The deletion 
disrupts a BcoD1 restriction enzyme site, yielding a 406 bp and a 347 bp product, 
representing mutant and wild-type alleles respectively. Unrelated Boston terriers and 
dogs from other breeds were genotyped using either restriction digest or Sanger 
sequencing.  
19.4 kb deletion  
To define the break points of the micro-deletion encompassing SGCD exons 7 and 
8 and the 3' intergenic sequence, primers were designed in flanking sequences 
(Additional File 1: Table S1). For genotyping, primer pairs were designed within the 
deletion to amplify only wild type alleles, as well as flanking the deletion for 
amplification of the mutant allele. Primer pairs were multiplexed for amplification using 
Phire Hot Start II DNA polymerase (ThermoFisher) and products were resolved by gel 
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electrophoresis. Products were initially verified via Sanger sequencing. The multiplex 




Muscle wasting, dysphagia, exercise intolerance, lethargy, and failure to thrive 
were accompanied by progressive gait abnormalities including a short, stilted gait in 
Cases 3 (Fig. 1a) and 4. While there was no clinical indication of cardiomyopathy, 
specific evaluations for heart disease by a veterinary cardiologist were not performed. 
Clinical chemistry included markedly elevated activities of serum alanine 
aminotransferase (ALT, 900IU/L, reference range 10-110 IU/L), aspartate 
aminotransferase (AST, 920 IU/L, reference range 16-50 IU/L), and creatine kinase (CK, 
>10,000 IU/L, reference range 50-275 IU/L). Progression of clinical signs necessitated 
euthanasia at approximately 1 year of age for Case 3 and 5 months of age for Case 4.  
 
Histology and immunofluorescence 
A dystrophic phenotype including degeneration, regeneration, and calcific 
deposits was evident in the skeletal muscle (Figs. 1b) and tongue (Fig 1c and d). Heart 
muscle was histologically normal (left ventricle, not shown) from Cases 3 and 4. 
Immunofluorescence staining of muscle cryosections showed markedly reduced or absent 
localization of α-, β-, γ-, and δ-sarcoglycans and sarcospan in Cases 3 and 4 (Fig. 2). 
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In contrast, staining for localization of α- and β-dystroglycans, dystrophin, caveolin 3, 
and perlecan was similar to control muscle (Fig. 3). Staining for collagen VI was 
increased in the endomysium compared to the control tissue, consistent with endomysial 
fibrosis. Results of histology, immunofluorescence staining, and western blotting of Case 
1 were described previously [8]. Staining for localization of δ-sarcoglycan in Case 1 was 




Figure 1. Histopathology of muscle biopsies from a female Boston terrier affected with 
sarcoglycanopathy (Case 3). A hunch back stance was evident in the dog (a). H&E stained 
cryosections from a representative limb muscle (b) showed degenerative changes and calcific deposits 
(black arrow). Similar degenerative changes and calcific deposits were observed in the tongue (c). The 





Figure 2. Loss of SGC staining in Cases 3 and 4. Representative H&E and immunofluorescence of 
cryosections from muscle of Cases 3 and 4, as well as control dog muscle. In control muscle, 
antibodies to the SGC (α-, β-, δ-, γ-sarcoglycans: αSG, βSG, δSG,  γSG), as well as sarcospan 
(SSPN), localize to the sarcolemma of the muscle fibers. Staining from each of these antibodies is 





Parentage testing was performed to determine relationships between Case 3 and 
three other dogs obtained from the same breeder. One relative was confirmed to be the 
dam of Case 3 and is referred to hereafter as the obligate carrier. The test excluded the 
Figure 3. Representative immunofluorescence of cryosections from muscle of Cases 3 and 4, and 
control dog muscle. Staining of α-dystroglycan (αDG), β-dystroglycan (βDG), dystrophin (DMD), 
caveolin 3 (CAV3), collagen VI (COL6), and perlecan (PCAN) in Cases 3 and 4. Antibodies to α- and 
β-dystroglycans, dystrophin, caveolin 3, and perlecan demonstrate sarcolemmal localization and 
intensity that is comparable to control tissue. An antibody to collagen VI shows increased localization 
to the endomysium compared to the control tissue, consistent with endomysial fibrosis. 
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remaining two dogs from being full siblings of Case 3 or progeny of the obligate carrier. 
Their relationship to the other dogs or to one another could not be determined.  
 
Variant identification from WES 
Disruption of any one of the sarcoglycans results in reduced immunostaining of 
the entire SGC, both in LGMD patients and in animal models of sarcoglycanopathy 
[23,24,25]. Therefore, genetic sequencing was necessary to identify the defective 
sarcoglycan gene.  
2 bp deletion 
The candidate genes (SGCA, SGCB, SGCD, SGCG) were sequenced to an 
approximate depth of 30X. For each gene, we manually screened the VCF file in IGV for 
variants fitting a pattern of inheritance consistent with a rare recessive allele. We 
expected both affected dogs to have inherited the causal mutation IBD from a common 
ancestor; therefore, we searched for variants homozygous in Cases 1 and 3, heterozygous 
in the obligate carrier, and heterozygous or homozygous wild-type in the two relatives. 
No variants fit these criteria.  
Because there was no known relationship between Cases 1 and 3, we considered 
that they may have different genetic causes for LGMD. Thus, we excluded Case 1 and 
searched again for the same pattern. Only one variant fit the pattern: a 2 bp deletion in 
exon 6 of SGCD (Figure 4). We validated the deletion through Sanger sequencing and 
determined that, in addition to the obligate carrier, one relative was heterozygous. The 
deletion predicts the substitution of an aspartate for a glutamate (E178D) and creates a 
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frameshift, leading to a premature stop codon two amino acids later (P180X) (Figure 4). 
We genotyped 199 Boston terriers and 127 dogs from 33 other breeds; none possessed 





19.4 kb deletion  
Using BAM files, we reexamined each candidate gene for variants homozygous in 
Case 1 and absent from the other Boston terriers. This approach revealed a complete 
absence of reads from the final two exons of SGCD (7 and 8) in Case 1, which was not 
apparent from the VCF file. No other variants fit the pattern. We hypothesized that the 
absence of reads represented a microdeletion and designed three primer pairs flanking 
exons 6, 7, and 8. PCR amplification yielded a product for exon 6 but not exons 7 or 8 in 
Case 1, providing further support for the presence of a deletion.  
Figure 4. Electropherogram showing the 2 bp SGCD deletion in Case 3.  The top panel shows the 
sequence from Case 3, while the lower panel shows the sequence from a healthy non-related Boston 
terrier.  The SGCD c.534_535delGA mutation leads to a frameshift and a premature stop codon two 
amino acids later. 
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It was not possible to characterize the deletion directly from WES because 
intergenic and intronic sequences are minimized. Sequence coverage indicated that the 
deletion was between SGCD exon 6 and TMD4. Furthermore, sporadic intronic and 
intergenic fragments were present 5' of exon 7, beginning at chr4:53282570, and in the 3' 
UTR, beginning at chr4:53261359, suggesting a maximum deletion size of 21,211 bp. 
Primer pairs flanking this estimated deletion size yielded large products (~3-5 kb), 
indicating a deletion approximately 2 kb smaller than suggested by WES. Sanger 
sequencing of the breakpoint revealed a substitution (chr4:53262018-53262020, 
ATG>CC), followed by 9 bp that were unchanged before a deletion of 19,403 bp 
(chr4:53262030-53281432) (Figure 5). We genotyped 201 Boston terriers and 91 dogs of 
19 other breeds and did not find any carriers. 
 
Figure 5. Schematic and sequence showing the breakpoints of the 19,403 bp SGCD deletion in 
Case 1.  Note that SGCD is annotated on the minus strand. Whole exome sequence from a healthy dog 
and Case 1 are aligned to the reference genome, visualized in Golden Helix GenomeBrowse [21,22]. 
Case 1 has no coverage of exons 7 and 8 and flanking regions. Sequence of the wild type and Case 1 
alleles show the precise breakpoints. Nucleotides 5′ and 3′ of the breakpoint are in bold blue and orange 
typeface, respectively. A substitution (chr4:53262020-53262018,CAT>GG) is found 9 bp downstream 
of the microdeletion and is shown in bold red typeface 
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Discussion 
Sarcoglycanopathies in humans are rare genetic disorders, with an incidence of 
one in every 178,000 human births [26]. To date, only small animal models are available 
for study: gene targeted mouse models for α-, β-, δ-, and γ-sarcoglycanopathy [27] and a 
spontaneous hamster model for δ-sarcoglycanopathy [28,29]. Here, we have 
demonstrated that a naturally occurring muscular dystrophy in a Boston terrier family is a 
sarcoglycanopathy, consistent with two previously published case reports in the breed. 
Given that cases have been described in three Boston terrier families, we expected a 
single recessive allele, present at a very low frequency within the breed, to underlie all 
cases. Instead, we uncovered independent mutations in the two families studied herein. 
Unfortunately DNA from Case 2 [14] was not available to determine whether this dog 
shared one of the mutations described herein, a different mutation in SGCD, or a 
pathogenic variant in another gene.  
Both families possessed mutations in SGCD, which encodes δ-sarcoglycan. 
Canine SGCD is located on CFA 4 and organized into eight exons that form a 1,297 bp 
mRNA transcript [30]. Human (XP_016865213.1) and dog (XP_013968526.1) amino 
acid sequences share 98% identity. Despite being the largest of the sarcoglycan genes, 
SGCD least commonly causes sarcoglycanopathy, with the majority of human cases 
attributed to changes in SGCA [31]. Thus, it is not only surprising that the Boston terriers 
had independent mutations causing sarcoglycanopathy, but that both had pathogenic 
alleles of SGCD. Curiously, the only other naturally occurring model of a 
sarcoglycanopathy, the Syrian hamster, also harbors an SGCD deletion [29].  
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Mutations of SGCD cause LGMD2F, and although clinical presentation is largely 
similar among the four sarcoglycanopathies, this is the only subtype not consistently 
characterized by concomitant cardiomyopathy [1]. The absence of heart involvement in 
Boston terriers is consistent with this classification; however, because the affected dogs 
were euthanized at an early age it is unknown if muscle degeneration would have 
progressed to involve the heart.  
Immunohistochemistry illustrated a lack of the SGC in both cases, but provides 
no indication as to whether SGCD is abnormal or absent altogether. Due to limited 
sample availability, collected tissues were prioritized for histopathological analysis and 
genomic DNA sequencing. RNAs were thus unavailable to investigate the consequence 
of the deletions on SGCD transcripts. The 2 bp pair deletion predicts a premature stop 
codon in exon 6, possibly causing nonsense-mediated decay. The 19.4 kb micro-deletion 
eliminates the last two exons of SGCD; the complete loss of an SGCD exon is rare [5]. It 
is hypothesized that exon 6 would splice to one or more cryptic sites, triggering either 
nonsense-mediated decay and/or the production of mutant protein. It is likely that mutant 
SGCD would cause assembly of the SGC to fail, resulting in LGMD [3,32].  
WES is a cost-effective method for the sequencing of multiple family members 
and has been used successfully to identify LGMD mutations in humans [33]. It was an 
advantageous choice over transcriptome sequencing in this study because SGCD 
transcripts would have been absent in Case 3 and possibly Case 1 as well, necessitating 
additional sequencing of SGCD to identify the causative mutations. In dogs, WES has led 
to the identification of alleles underlying progressive retinal atrophy, primary angle 
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closure glaucoma, and nemaline rod myopathy using small numbers of related cases 
[34,35,36,37,38] but is not ideal for detecting intergenic deletions or genomic 
rearrangements [39]. The development of improved WES enrichment kits for dogs 
[39,40] will facilitate future detection of disease variants in canine models. 
 
Conclusion 
The identification of canine models of disease holds promise for new advances in 
the understanding and treatment of analogous human diseases. For example, the well-
characterized Golden retriever model of Duchenne muscular dystrophy (DMD) has 
proven to be an invaluable resource for gene therapy and other trials [41,42]. Here we 




bp: base pair; CAG: Center for Animal Genetics, CAG GmbH; CNL: Comparative 
Neuromuscular Laboratory, University of California San Diego; DMD: Duchenne 
muscular dystrophy; DNA: deoxyribonucleic acid; H&E: hematoxylin and eosin; IBD: 
identical by descent; IGV: Integrative Genomics Viewer; LGMD: limb-girdle muscular 
dystrophy; PCR: polymerase chain reaction; SGC: sarcoglycan complex; SGCA: α-
sarcoglycan; SGCB: β-sarcoglycan; SGCD: δ-sarcoglycan; SGCE: ε-sarcoglycan; 
SGCG: γ-sarcoglycan; SGCZ: ζ-sarcoglycan; UTR: untranslated region; VCF: variant 
call format; WES: Whole exome sequencing 
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Juvenile dermatomyositis (JDM) is a chronic inflammatory myopathy and 
vasculopathy driven by genetic and environmental influences. Here, we investigated the 
genetic underpinnings of an analogous, spontaneous disease of dogs also termed 
dermatomyositis (DMS). As in JDM, we observed a significant association with a 
haplotype of the major histocompatibility complex (MHC) (DLA-DRB1*002:01/-
DQA1*009:01/-DQB1*001:01), particularly in homozygosity (P-val=0.0001). However, 
the high incidence of the haplotype among healthy dogs indicated that additional genetic 
risk factors are likely involved in disease progression. We conducted genome-wide 
association studies in two modern breeds having common ancestry and detected strong 
associations with novel loci on canine chromosomes 10 (P-val=2.3X10-12) and 31 (P-
val=3.95X10-8). Through whole genome resequencing, we identified primary candidate 
polymorphisms in conserved regions of PAN2 (encoding p.Arg492Cys) and MAP3K7CL 
(c.383_392ACTCCACAAA>GACT) on chromosomes 10 and 31, respectively. Analyses 
of these polymorphisms and the MHC haplotypes revealed that nine of 27 genotypic 
combinations confer high or moderate probability of disease and explain 93% of cases 
studied. The pattern of disease risk across PAN2 and MAP3K7CL genotypes provided 
clear evidence for a significant epistatic foundation for this disease, a risk further 
impacted by MHC haplotypes. We also observed a genotype-phenotype correlation 
wherein an earlier age of onset is correlated with an increased number of risk alleles at 
PAN2 and MAP3K7CL. High frequencies of multiple genetic risk factors are unique to 
affected breeds and likely arose coincident with artificial selection for desirable 
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phenotypes. Described herein is the first three-locus association with a complex canine 
disease and two novel loci that provide targets for exploration in JDM and related 
immunological dysfunction.  
 
Author summary 
 Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle 
influenced by both genetic and environmental components. Although genes independent 
of the MHC are thought to contribute to disease pathogenesis, their identification has 
been complicated by a paucity of biological samples, disease heterogeneity, and 
genetically diverse subjects. A naturally occurring inflammatory disease of domestic 
dogs, also termed dermatomyositis (DMS), is analogous to JDM and is the only animal 
model available for genetic study. We first determined that, as in JDM, a particular MHC 
haplotype confers susceptibility to DMS. Capitalizing on the genetic isolation of dog 
breeds and extremely low MHC diversity within affected breeds, we used multibreed 
genome-wide association studies to identify two novel loci. Through genome 
resequencing and additional genotyping, we uncovered highly associated polymorphisms 
in conserved positions of PAN2 and MAP3K7CL. Analysis of three-locus genotypes 
revealed uniquely high frequencies among affected breeds and nine allelic combinations 
that confer moderate or high risk for DMS. The pattern of disease probability illustrates 
the presence of gene-gene interaction, as well as an inverse correlation between age of 
onset and number of risk alleles. This study highlights the utility of canine models for 
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mapping susceptibility loci in complex diseases and detecting patterns of genetic 
interactions obscured in diverse human populations. 
 
Introduction  
Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy that causes a 
characteristic skin rash (heliotrope rash across the eyelids and Gottron’s papules on the 
bony prominences) and proximal muscle weakness [1]. It is the most frequently 
diagnosed childhood inflammatory myopathy, comprising 80% of all cases [1] and 
affecting 3.2 in every million children between the ages of 2 and 17 within the USA [2]. 
Prognosis is positively correlated with early diagnosis and swift treatment with 
corticosteroids and/or immunosuppressants [1,3]. While treatment of JDM is much 
improved overall, many children still suffer from chronic flare-ups [1].  
Though the etiology is unknown, JDM is thought to be triggered by exposure to a 
virus or other environmental agent. Manlhiot et al. [4] reported that 71% of JDM patients 
had a clinical history consistent with infection prior to symptoms. Investigations into the 
class II major histocompatibility loci (MHC), TNF, and IL1 identified several 
susceptibility and protective alleles, but their collective contribution to pathogenesis is 
poorly understood [5-8]. Recent genome-wide association studies (GWASs) to identify 
additional susceptibility loci in JDM confirmed a strong association with the MHC but 
failed to detect novel major risk factors, likely because of a paucity of biological samples 
and genetically heterogeneous populations [9,10].  
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In domestic dogs, an inflammatory vasculopathy of the skin and muscle, also 
termed dermatomyositis (DMS), is clinically, histologically, and immunologically similar 
to JDM and provides the only animal model available to study genetic risk factors [11-
16]. The earliest clinical signs of DMS are crusting and scaling on the face, ears, tail tip, 
and/or across the bony prominences of the limbs and feet [17-19] (S1 Fig). Alopecia and 
more extensive skin lesions may develop over time, resulting in dermal scarring 
associated with erythema and mottled pigmentation [17,19]. Lesions persist for weeks to 
months, and may or may not chronically recur [17]. Muscle wasting manifests as atrophy 
of the head musculature; difficulty eating, drinking, and swallowing; and an atypical, 
high-stepping gait [17,19].  
Similar to JDM, DMS is an immune-mediated disease [13,18,20] that typically 
develops following an environmental trigger, such as vaccination or viral infection, and is 
exacerbated by subsequent stressors like exposure to UV light [13,17,21,22]. Anecdotal 
reports indicate that rabies vaccination, parvovirus infection, owner surrender, or 
mistreatment commonly precede disease onset. Consistent with an environmental trigger, 
age at onset is variable with many cases occurring between seven weeks and six months 
of age, but others not developing until well into adulthood [17-19,23].  
DMS is diagnosed almost exclusively in the genetically [24] and phenotypically 
similar collie and Shetland sheepdog breeds, suggesting the presence of a strong heritable 
component(s) arising from ancestors common to both breeds. A 1980s study of disease 
transmission in the collie eliminated simple Mendelian modes of inheritance [14]. In two 
test matings, an affected male collie sired litters from an affected collie and a healthy 
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Labrador retriever. All six collie puppies were affected with variable degrees of severity, 
while three of the four mixed breed puppies developed milder forms of DMS. 
Retrospective pedigree analyses of the collie sire and dam showed a complete absence of 
affected ancestors [14].  
The availability of a naturally-occurring canine model provides a new opportunity 
for the identification of genetic risk factors of JDM. The conserved genomic backgrounds 
of genetically isolated dog breeds have enabled detection of risk loci in complex diseases 
that are often obscured by heterogeneity within human cohorts [25-30]. Here, we 
evaluated class II MHC haplotypes, performed multibreed GWASs, and generated whole 
genome and transcriptome sequencing data to dissect the genetic basis of DMS. We 
uncovered common polymorphisms of the MHC and two novel loci that are strongly 
associated with DMS, as well as patterns of allelic inheritance that explain 93% of cases 
studied. A genetic test is now available to determine the likelihood of a dog developing 
DMS and to facilitate breeding decisions that avoid progeny having high-risk genotypes. 
 
Results and Discussion 
Association of a major histocompatibility complex haplotype 
Given the involvement of MHC genes in JDM, we first determined alleles of the 
highly polymorphic canine MHC class II dog leukocyte antigen (DLA) genes: DLA-
DRB1, -DQA1, and -DQB1. Two locus (DLA-DRB1 and -DQB1) and three locus (DLA-
DRB1, -DQA1, and -DQB1) haplotypes were first generated for 50 collies and 117 
Shetland sheepdogs, respectively. Because all observed haplotypes contained a unique 
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DLA-DRB1 allele, the 355 remaining dogs were genotyped for this locus only and the 
haplotype was inferred (Table 1).  
 
 
We observed remarkably low DLA diversity among collies, with only three 
haplotypes present in 225 collies worldwide. This lack of heterogeneity precluded 
detection of associations with DMS, as 91% of collies were homozygous for the 
haplotype DLA-DRB1*002:01/-DQA1*009:01/-DQB*001:01. In 297 Shetland 
sheepdogs, we identified two predominant haplotypes, 002:01/009:01/001:01 and 
023:01/003:01/005:01. The former was over-represented among cases (P-val=0.0010, 
OR=2.20), primarily because of increased homozygosity (P-val=0.0001, OR=2.98). We 
therefore conclude that 002:01/009:01/001:01 is a risk factor for DMS and that 
homozygosity confers increased susceptibility. Under the assumption that the causal 
COLLIE 
DLA-DRB1*/-DQA1*/-DQB1* Cases (2n=80) 
Controls 
(2n=370) OR 95% CI P-value 
002:01/009:01/001:01 74 353 0.59 0.23-1.56 0.40 
006:01/050:11/007:01 0 3 - - - 
015:01/009:01/001:01 6 14 2.06 0.77-5.54 0.23 
SHETLAND SHEEPDOG 
DLA-DRB1*/-DQA1*/-DQB1* Cases (2n=184) 
Controls 
(2n=410) OR 95% CI P-value 
002:01/009:01/001:01 † 158 301  2.20 1.38-3.52 0.0010 
015:01/009:01/001:01 1 6 0.37 0.04-3.08 0.4454 
023:01/003:01/005:01 24 102 0.45 0.28-0.73 0.0011 
Other haplotypes 1 1 - - - 
Table 1. Frequency of DLA-DRB1/-DQA1/-DQB1 haplotypes in collies and Shetland sheepdogs.  
The number of times each haplotype was observed is reported for cases and controls with odds ratios 
(OR), 95% confidence intervals, and Fisher’s exact two-tailed P-values. Significant statistics are 
bolded. 
†71 out of 92 cases and 109 out of 205 controls were homozygous for the 002:01/009:01/001:01 
haplotype (OR=2.98, 95% CI=1.70-5.21, P-val=0.0001). 
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alleles derive from an ancestor common to both breeds, we extrapolate the observed DLA 
risk to collies. The high frequency of the DLA risk haplotype in both populations 
indicates that additional loci must influence disease progression. 
 
Genome-wide association studies reveal signals on chromosomes 10 & 31 
We conducted an independent GWAS for each breed, using a total of 97 cases (31 
collies, 66 Shetland sheepdogs), 68 controls (23 collies, 45 Shetland sheepdogs), and 
98,520 SNPs after filtering. In collies, a single signal (P-val=1.47X10-8) composed of 17 
SNPs at the centromeric end of chromosome 10 exceeded Bonferroni significance (Fig 
1A). In Shetland sheepdogs, this association was replicated (P-val=2.56X10-7), and a 
second signal (P-val=1.83X10-9) composed of 11 SNPs surpassing Bonferroni 
significance was detected on chromosome 31 (Fig 1B). Both associations persisted in a 
combined breed analysis (chr10: P-val=2.3X10-12, chr31: P-val=3.95X10-8) (S1 Table, S2 
Fig); although the breeds possessed a common haplotype on chromosome 31, the 
Shetland sheepdogs appeared to drive this association. No associated SNPs were detected 
near the MHC loci on chromosome 12, likely a result of high homogeneity in our cohort 






On chromosome 10, 97% of all affected dogs were homozygous or heterozygous 
for the risk alleles of the lead SNPs. On chromosome 31, 88% of affected Shetland 
sheepdogs, but only 39% of affected collies, shared the risk alleles of the lead SNPs. As 
neither locus appeared to be independently necessary for disease development, we 
surveyed the extent of regional linkage disequilibrium (LD) to demarcate candidate 
intervals of ~1.33 Mb on chromosome 10 (Fig 2A) and ~696 kb on chromosome 31 (Fig 
2B), harboring ~65 and 6 genes, respectively. The large size of the chromosome 10 
region is attributed to lower recombination rates near the centromere and a dearth of 
informative SNPs.  
 
Figure 1. Manhattan plots of DMS GWASs in two breeds. (a) Collies: 31 cases and 23 controls. 
(b) Shetland sheepdogs: 66 cases and 45 controls. The –log10P-values (y-axis) for 98,520 Illumina 
SNPs are plotted against chromosome position (x-axis). The threshold for Bonferroni significance 








Figure 2. Regional plots depicting LD at two associated loci. Association results (-log10P) for (a) 
combined breed GWAS on chromosome 10 and (b) Shetland sheepdog GWAS on chromosome 31 are 
color-coded based on pairwise LD (r2) with the lead SNPs (purple diamond). Dotted lines demarcate the 
candidate interval. Genes within the region (based on hg18) are shown below the plot with chromosome 
positions reported in canFam3. On chromosome 10, the gene track is zoomed in to represent the 




Identification of candidate variants in PAN2 and MAP3K7CL 
Whole genome resequencing was performed for four affected dogs (three collies 
and one Shetland sheepdog) and two unaffected collies, resulting in 17X to 41X 
coverage. Variants were filtered for those lying within our delineated intervals (chr10:1-
1,333,693; chr31:24,026,411-24,722,836) and following the inheritance pattern of the 
most significantly associated SNPs in the affected dogs (S2 and S3 Tables). Five 
intergenic and two intronic variants were unique to these breeds (i.e., not present in the 
Boxer reference genome, dbSNP, or 27 whole genome sequences from 16 other breeds); 
however, most were in repetitive regions and none were in conserved positions. Thus, the 
pathogenic variants were likely to be common polymorphisms, so we next prioritized 
variants within predicted exons and splice sites of genes expressed in skin for further 
study.  
To confirm exon/intron boundaries predicted by Ensembl 79 and establish 
expression of variants in affected tissue, we generated RNAseq data. We obtained a 
minimum of 89 million reads per tissue from active skin lesions of two affected dogs 
(one collie and one Shetland sheepdog) and skin from one unaffected Australian shepherd 
dog. All genes expressed in skin within the candidate regions were also expressed in 
affected tissues. Seventeen exonic variants were expressed; seven of these were 





Position  Gene A1/A2 AA  change 
Poly-
Phen2 PANTHER SIFT  P-value 
CHROMOSOME 10 Cases n=93 Controls n=63 
95042 ITGA7 T/C Val/Val - - - - 
121835 RDH5 G/A Ala/Ala - - - - 
222809 MMP19 T/G Gln/Pro 0 91 0.43 - 
331135 SUOX A/G His/Arg 0 85 N/A - 
565958 ANKRD52 G/C Ser/Cys 0.92 361 0.02 1.93X10-17 
627760 PAN2 G/A Arg/Cys 1 1628 0 1.93X10-17 
1127082 RDH16 C/T Ala/Ala - - - - 
1228277 NAB2 G/C Gly/Arg 0 85 N/A - 
1239562 STAT6 G/A Thr/Met 0.98 361 0.05 1.52X10-4 
1286150 LRP1 C/T Asn/Asn - - - - 
1333693 LRP1 G/A Gln/Gln - - - - 
CHROMOSOME 31 Cases n=63 Controls n=45 
24068039 CCT8 T/C Ala/Ala - - - - 
24132273 MAP3K7CL Indel/- 5′ UTR N/A N/A N/A 2.09X10-11 
24132343 MAP3K7CL A/C 5′ UTR N/A N/A N/A 1 
24292521 BACH1 A/G Asn/Asp 0.007 324 0.21 - 
24294659 BACH1 A/G Glu/Glu - - - - 
24295208 BACH1 A/G Pro/Pro - - - - 
 
We genotyped a subset of our mapping population for three nonsynonymous 
SNPs on chromosome 10 (ANKRD52 g.565958G>C, PAN2 g.627760G>A, and STAT6 
g.1239562G>A) that were predicted to be deleterious or probably damaging by more than 
one in silico program. The ANKRD52 and PAN2 variants were more strongly associated 
with DMS than the lead SNP. These variants were in perfect linkage disequilibrium with 
each other; however, PAN2 g.627760G>A was assigned damaging scores with higher 
confidence by in silico programs (Table 2). We therefore focused further studies on 
Table 2. Expressed exonic changes on chromosomes 10 and 31. Alleles 1 (A1=minor allele) and 2 
(A2=reference allele) are reported. Amino acid changes are based on the dog reference genome. P-
values are reported for matched populations. Variants with PolyPhen2 scores ranging from 0.85-1, 
PANTHER preservation time (in millions of years) >450my, and SIFT scores ranging from 0-0.05 are 
considered deleterious/probably damaging. Variants more strongly associated with DMS than the most 
associated SNPs from the array are bolded. 
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PAN2 g.627760G>A, encoding p.Arg492Cys (XP_531635.3), although ANKRD52 
cannot be excluded. On chromosome 31, we genotyped Shetland sheepdogs for a SNP 
(g.24132343A>C) and an indel (c.383_392ACTCCACAAA>GACT, XM_846337.4), 
both located in a 5′ non-coding exon of MAP3K7CL. Only the indel was associated with 
DMS (Table 2, S3 Fig). In an expanded, combined population (132 affected and 390 
unaffected collies and Shetland sheepdogs), both the PAN2 (P-val=2.08X10-35) and 
MAP3K7CL (P-val=1.45X10-33) variants were highly associated with DMS (S4 Table). 
PAN2 (or USP52) encodes the catalytic subunit of the poly(A) nuclease 
deadenylation complex (PAN2-PAN3) and is one of two exonucleases involved in 
mRNA degradation in eukaryotes [34,35]. Deadenylation plays a role in translational 
regulation of inflammatory response [36]. Independent of this function, PAN2 also 
stabilizes HIF1A transcripts via their 3′-UTR, which contain AU-rich elements (AREs), 
and may be involved in regulating other transcripts having AREs [37]. HIF1A, a key 
regulator of inflammation [38], and other ARE-containing transcripts, such as IL-6 [39], 
are upregulated in JDM [40, 41]. PAN2 is widely expressed and highly evolutionarily 
conserved [35]; human (NP_001120932.1) and dog (XP_013972628.1) amino acid 
sequences share 98% identity.  
MAP3K7CL (also known as TAK1L or C21orf7) is a poorly studied kinase gene 
that is transcriptionally active in immunological tissues and expressed primarily in 
peripheral blood leukocytes [42,43]. Human (NP_001273546.1) and dog 
(XP_013965340.1) MAP3K7CL protein sequences share >90% identity. The 
transcription factors RUNX3 and EP300 bind the 5′ non-coding exon of human 
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MAP3K7CL (UCSC Genome Browser ENCODE Transcription Factor ChIP-seq track). 
In this exon, the c.383_392ACTCCACAAA>GACT indel causes the loss of six 
conserved base pairs, omitting a RUNX3 binding motif (P-val=2.07X10-3 from 
TOMTOM [44]) (S3 Fig). RUNX3 has known roles in inflammatory response (e.g., 
thymopoiesis [45,46] and the TGF-β signaling cascade [47]), and it has been directly 
implicated in a number of immune-related diseases [48-50]. Furthermore, SNPs 
disrupting RUNX binding motifs in target genes confer susceptibility to autoimmune 
rheumatic diseases, including psoriasis [51] and systemic lupus erythematosus [52]. 
 
Analysis of three-locus genotypes reveal gene-gene interactions 
We next considered three-locus genotypes in our expanded, combined population 
(132 affected and 390 unaffected dogs) where A=the PAN2 variant encoding 
p.Arg492Cys, B=MAP3K7CL c.383_392ACTCCACAAA>GACT, and C=DLA-
DRB1*002:01, lower-case letters denote wild type alleles (c represents any alternate 
allele of DLA-DRB1). Only 4% of dogs possessed a three-locus genotype with cc, barring 
further analysis of those nine genotypes. We considered nine of the remaining genotypes 
to be low-risk, as less than 6% of dogs with these allelic combinations had DMS (Table 
3). Among healthy dogs (Fig 3A), the most frequently observed genotypes were AabbCC 
(24%) and aabbCC (15%). Based on penetrance, we classified five genotypes as 
conferring moderate risk (33-50%) and four as high risk (90-100%) for DMS. All cases 
possessed at least two risk alleles and all but one were homozygous for at least one risk 
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allele. The most common genotypes of affected dogs (Fig 3B) were AaBBCC (20% of 
cases), followed by AAbbCC, AABbCC, and AABBCC (17% of cases each). 
 Interestingly, only affected dogs possessed AABBCc or AABBCC (n=29), 
indicating that DMS is fully penetrant in dogs having these combinations. Epistasis plots 
illustrated that genotypes with at least one a or b allele confer a lower probability of 
disease when a c allele is present, compared to their CC counterparts (Fig 3, compare C 
and D). The plots also depicted a greater probability of disease than expected under a 
strictly additive model, providing evidence for additive-by-additive epistasis between the 
chromosome 10 and 31 loci [53,54]. We noted at least one ARE in MAP3K7CL, 
presenting a mechanism for interaction with PAN2. No difference in gene interactions 
was observed between the sexes (S4 Fig).  
Information regarding age at onset or diagnosis was available for 91 dogs. We 
compared dogs having two, three, or four risk alleles across PAN2 and MAP3K7CL and 
observed an inverse correlation between age of onset and number of risk alleles (S5 Fig). 
Dogs having four risk alleles developed DMS at a significantly younger median age (5 
months) than did dogs with only two risk alleles (18.5 months). The complete penetrance 
of AABB genotypes, combined with an early age of onset, suggest that these dogs may be 







Figure 3. Three-locus genotype disease probabilities and frequencies (132 cases, 390 controls). 
Word clouds of three-locus genotypes illustrate frequency differences between (A) controls and (B) 
cases with high-risk genotypes in red, moderate-risk in yellow, and low-risk in blue. Probability of 
disease (y-axis) for all combinations of PAN2 (x-axis) and MAP3K7CL genotypes are plotted in dogs 























aabbcc 0 1 0 1 - - 0-0.842 1 
aabbCc 0 5 0 18 - low 0-0.148 0.0023 
aabbCC 1 43 1 17 - low 0.004-0.112 0 
Aabbcc 0 0 0 3 - - 0-0.708 0.577 
AabbCc 0 3 1 15 - low 0.001-0.260 0.060 
AabbCC 2 71 2 23 - low 0.011-0.101 0 
aaBbcc 0 0 0 5 -  low 0-0.522 0.399 
aaBbCc 0 1 0 21 - low 0-0.154 0.002 
aaBbCC 0 10 0 32 - low 0.084 0 
AaBbcc 0 0 0 1 - - 0-0.975 1 
AaBbCc 0 0 0 14 - low 0-0.232 0.028 
AaBbCC 0 13 2 23 - low 0.006-0.177 0.002 
AAbbcc 1 0 0 0 - - 0.025-1 0.253 
AAbbCc 4 6 1 1 42 moderate 0.152-0.723 0.194 
AAbbCC 15 31 7 3 39 moderate 0.265-0.532 0.021 
aaBBcc 0 0 0 1 - - 0-0.975 1 
aaBBCc 0 0 0 6 - low 0.0459 0.348 
aaBBCC 0 0 6 7 46 moderate 0.192-0.749 0.107 
AaBBcc 0 0 2 1 - - 0.094-0.992 0.160 
AaBBCc 0 0 5 5 50 moderate 0.187-0.813 0.136 
AaBBCC 3 0 23 3 90 high 0.762-0.978 0 
AABbcc 0 0 3 0 - - 0.292-1 0.016 
AABbCc 0 0 2 4 33 moderate 0.043-0.777 0.647 
AABbCC 11 1 11 1 92 high 0.730-0.990 0 
AABBcc 0 0 0 0 - - - - 
AABBCc 0 0 7 0 100 high 0.590-1 0.0001 






Table 3.  Distribution of three-locus genotypes in 132 cases and 390 controls with penetrance, 
95% confidence intervals, and P-values. Significant values in bold. 
*Risk interpretations were only made for three-locus genotypes observed at least five times. 
**P-values are calculated for each genotype compared to the population as a whole (0.253, 132 affected 
dogs out of 522 total dogs). 
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Collies and Shetland sheepdogs have uniquely high frequencies of associated alleles 
All three identified variants associated with DMS are polymorphisms present in 
several breeds, raising the question: why are other breeds rarely, if ever, affected by 
DMS? We genotyped five or more unrelated individuals from each of 30 diverse breeds 
for all three loci (Fig 4). The only other breeds to possess all three risk alleles were 
Cardigan Welsh corgis and Cairn terriers. Three Jack Russell terriers had moderate-risk 
genotypes (AAbbCc), as did one Cardigan Welsh corgi (AABbCc); both breeds are 
occasionally diagnosed with dermatomyositis-like disease [56,57].  None of the 229 
individuals possessed a high-risk genotype (S5 Table). Interestingly, Labrador retrievers 
had both B and C, which could have enabled moderate or high risk genotypes (AaBBCc 
or AaBBCC) in puppies from the outcross mating described by Haupt et al. [14]. 
Combined frequencies of risk alleles in other breeds were dramatically lower than 
those observed among collie and Shetland sheepdog populations, and homozygosity for a 
risk allele (a characteristic of all moderate- to high-risk genotypes) was rare. 
Additionally, breeds having a high frequency of one risk allele had few or no risk alleles 
at the other loci. For example, Cairn terriers had a high frequency of A (75%) but low 
frequencies of B (19%) and C (3%), and no high- or moderate-risk genotypes were 
observed among 18 individuals. These findings suggest that independently the 







Figure 4. Frequencies of DMS-associated polymorphisms across breeds. The number of alleles used 
to calculate the frequencies is shown to the left of the breed name, if > 10. Risk allele frequencies (x-
axis) for each gene are represented by a single, segmented colored bar: the PAN2 variant encoding 
p.Arg492Cys is represented in purple, MAP3K7CL c.383_392ACTCCACAAA>GACT in gray, 
and DLA-DRB1*002:01 in orange. The number of homozygous dogs observed is reported on the 
corresponding color bar. Asterisks denote breeds lacking DLA-DRB1*002:01 in this study, but which 
were previously reported to possess the allele [55]. 
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It is likely that recent artificial selection for phenotypes shared by collies and 
Shetland sheepdogs led to increased frequencies of A. We propose that persistence of A in 
these two breeds is attributed to linkage disequilibrium (D′=0.998) between wildtype 
PAN2 (a) and another chromosome 10 allele, Merle of PMEL. In heterozygosity, Merle 
causes a popular pigmentation pattern (see collie in Fig 1A), but homozygosity for the 
allele results in severe hypopigmentation often with auditory and ocular defects [58]. 
Wildtype PMEL occurred on chromosomes with either A or a, whereas Merle was only 
found in conjunction with a. Accordingly, the Merle phenotype was underrepresented in 
affected dogs (P-value=0.0018), 64% of which were homozygous for A. Consistent 
selection for heterozygosity (but not homozygosity) for Merle would simultaneously 
encourage maintenance of both PAN2 alleles. To our knowledge, there are no loci on 
chromosome 31 under positive selection for maintenance of a characteristic phenotype of 
collies and/or Shetland sheepdogs. 
Across five collie genomes, we observed a 1.2 Mb selective sweep on 
chromosome 12 (S6 Fig) encompassing the MHC class II loci and leading to near fixation 
of the 002:01/009:01/001:01 haplotype. We suggest that essentially all purebred collies 
have increased susceptibility for DMS, conferred by homozygosity for allele C. The 
Shetland sheepdog population has retained a less common second haplotype that permits 
heterozygosity at the DLA loci, associated with a lower risk for developing DMS. 
Ironically, this reduced risk may have masked the presence of otherwise high-risk 
genotypes (i.e., AABb and AaBB) and hindered selection against A and B alleles.  
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We observed striking allele frequency differences between the two affected 
breeds at PAN2 and MAP3K7CL: collies had a higher frequency of A, 42% (25% in 
Shetland sheepdogs), whereas Shetland sheepdogs had a higher frequency of B, 38% (5% 
in collies) (Fig 4). Consequently, the frequency of observed allelic combinations varied 
between the breeds. The most common genotypes in healthy dogs were aaBbCC in 
Shetland sheepdogs, 16% (5% in collies), and AabbCC in collies, 38% (11% in Shetland 
sheepdogs). Among affected dogs, AaBBCC predominated in Shetland sheepdogs, 25% 
(8% in collies), whereas AAbbCC was the most frequent genotype in diseased collies, 
38% (8% in Shetland sheepdogs). The latter finding is interesting given that AAbbCC is 
only a moderate-risk genotype. Among collies having this genotype, 67% were 
unaffected by age 8, whereas only 30% of Shetland sheepdogs with this genotype were 
disease-free. This discrepancy in disease probabilities between breeds was unique to this 
genotype. Further studies will be necessary to determine if other loci confer additional 
risk for or protection from DMS. 
The contribution of alleles from multiple loci explains the spontaneous 
appearance of the disease in lines with no prior history [14] and has hindered elimination 
of DMS in the absence of a genetic test. For example, a mating between two healthy dogs 
having low risk genotypes (e.g., AaBbCC x AaBbCC) can produce puppies with low, 
moderate, or high risk for DMS. This study has led to the first three-locus genetic test for 
a complex disease of dogs, which will allow breeders to carefully reduce the frequency of 
A and B among collie and Shetland sheepdog populations while preserving genetic 
diversity and desirable breed characteristics. 
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In a canine model of JDM, we have identified a complex pattern of causation 
involving three independent loci, two of which offer new targets for exploration in JDM. 
Furthermore, these data provide support for the involvement of genetic risk factors 
independent of the MHC in human inflammatory myopathies. While further experiments 
are necessary to determine the exact contribution of the chromosome 10 and 31 loci, our 
findings suggest that DMS may result from an inability to properly regulate inflammatory 
response. This work highlights the utility of the canine model for unraveling genetic 





All samples were obtained with informed consent according to protocols 
approved by the Clemson University Institutional Review Board (IBC2008-17) and 
IACUC (2012-039). 
 
Study population.  
Three populations were assembled: DMS-affected dogs (92 Shetland sheepdogs, 
40 collies), control dogs for GWAS (45 Shetland sheepdogs, 23 collies), and unaffected 
dogs (160 Shetland sheepdogs, 162 collies). Affected dogs were diagnosed either through 
histopathology (75 Shetland sheepdogs, 30 collies) or by a veterinarian based on clinical 
signs and elimination of demodectic mange, a differential diagnosis. Pedigrees were 
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collected when available; some samples were obtained from affected dogs surrendered to 
rescue organizations without paperwork. Twenty percent of affected dogs were collected 
internationally, and in each case a regionally-matched control sample was obtained.  
Control dogs for GWAS were eight years of age or older at time of collection, had no 
known family history of DMS, had no personal history of skin disease, and were 
unrelated to other study participants within two (most often three) generations. Pedigrees 
were obtained from all control dogs. The population of unaffected dogs had no clinical 
signs of DMS and were eight years of age or older at time of collection. This subset was 
collected without regard to family history of DMS, presence of other skin disorders, or 
relationship to other study participants. Archival samples from 229 dogs of 30 other 
breeds were not closely related to each other to our knowledge. 
Whole blood or buccal cells were obtained from each dog, and genomic DNA was 
isolated according to the Puregene DNA Isolation protocol (Gentra). Skin punch biopsies 
from active lesions or healthy tissue were also obtained from one Shetland sheepdog, one 
collie, and one Australian shepherd dog and preserved in RNAlater (Ambion).  
 
DLA class II genotyping.  
The hypervariable regions of DLA-DRB1, -DQA1 and -DQB1 were sequenced 
and genotyped according to protocols previously described [59-61]. DLA-DQA1 was 
largely uninformative in collies and was inferred. Association of a haplotype or allele 
state with DMS was assessed through Fisher’s exact tests, using VassarStats (Web Site 
for Statistical Computation, Vassar College, Poughkeepsie, NY). 
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Genome-wide association and LD analyses.  
Genotyping was performed for 166 dogs (85 males and 81 females) using the 
Illumina CanineHD BeadChip, containing 173,662 SNPs. One sample having call rates 
<95% was excluded. SNPs having call rates <95%, minor allele frequencies <5%, and/or 
significant deviation from Hardy-Weinberg equilibrium (P-value <0.0001) in the control 
dogs were excluded. No evidence of genomic inflation was observed in the combined 
Shetland sheepdog and collie analysis (λ=1.04). Fisher’s exact P-values were calculated 
under a dominant model.  
LD pairwise analysis was performed to calculate r2 values, which were plotted 
using LocusZoom [62]. We calculated r2 values between SNPs on chromosome 10 using 
all controls. For chromosome 31, r2 values were calculated using only control Shetland 
sheepdogs because no association was detected in collies alone. Assuming that the 
pathogenic variant would be in high LD with the lead SNP, candidate regions were 
characterized by SNPs with pairwise r2 ≥ 0.6 and defined by the first flanking associated 
SNPs in lower LD. Filtering and statistical analyses were conducted with SNP & 
Variation Suite v8 (SVS, Golden Helix). All chromosome positions throughout the text 
are reported in CanFam3.1.  
 
Whole genome resequencing.  
Three affected and two control collies were selected for whole genome 
resequencing along with one affected Shetland sheepdog. Genomic DNA fragments of 
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approximately 500bp were gel size selected for each sample and sequenced on two lanes 
of an Illumina HiSeq 2000, generating 2x100 (collies) and 2x125 bp (Shetland sheepdog) 
paired-end reads. 531 to 997 million total reads were generated for the five collies. Over 
one billion total reads were generated for the Shetland sheepdog. Paired reads were 
aligned to the indexed reference (CanFam3.1) with Bowtie2 [63] under sensitive 
parameters. The alignments were sorted and indexed with SAMtools [64,65] to be 
visualized in the Interactive Genomics Viewer [66].  
 
RNA isolation and sequencing.  
Total RNA was extracted from 30-40mg of skin punch biopsy tissue from active 
lesions (collie and Shetland sheepdog) or healthy skin (Australian shepherd) using the 
ToTALLY RNA kit (Ambion), according to the manufacturer’s protocols. RNA samples 
were treated with DNase to remove DNA contamination, using the DNA-free kit 
(Ambion). Samples were quantitated on a NanoDrop 1000 spectrophotometer (Fisher 
Scientific). 
Three RNAseq libraries were constructed per dog using normalized total RNA 
and the manufacturer's protocol for one of the following: TruSeq RNA library prep kit 
v2.0 (Illumina) or TruSeq stranded total RNA library prep kit (Illumina). An Agilent 
Bioanalyzer 2100 was used for size validation. Each sample was sequenced at 2 x 125bp 
paired-end on an Illimina HiSeq 2500 to a depth of at least 22 million reads.  
FastQC from the Babraham Institute was used to assess read quality before and 
after preprocessing by Trimmomatic [67], which removed low quality bases and 
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remaining sequence adapters. Trimmed reads for each sample were aligned to 
CanFam3.1 using gsnap [68], and SAMtools [64,65] was used to generate sorted and 
indexed bam files.  
 
Variant filtering and genotyping.   
SAMtools and BCFtools [64,65] were used to generate variant call files for each 
sample, which were analyzed in SVS. On chromosome 10 (1-1,333,693 bp) variants that 
were heterozygous in affected collies 1 & 2 and homozygous in affected collie 3 and the 
affected Shetland sheepdog (i.e., reference/reference or alternate/alternate), consistent 
with the allele states at the lead SNPs, were selected. On chromosome 31 (24,026,411-
24,722,836 bp), all homozygous variants in the Shetland sheepdog were selected. 
Ensembl 79 was used to identify variants lying within predicted exons and 10 bp flanking 
sequences to capture splice sites. RNAseq data were manually inspected in IGV to 
determine whether predicted exonic variants were expressed in the affected dogs. 
Alternate variants were investigated using dbSNP and 27 genomes of 16 other breeds 
(either sequenced as part of ongoing studies or shared by other research groups) to 
determine whether any were unique to collies and Shetland sheepdogs. SIFT [31], 
PolyPhen [32], and PANTHER [33] were used to predict the impact of the amino acid 
substitutions. Genotyping of variants in additional dogs was accomplished by restriction 




Age of onset.  
Because age is not distributed as a normal random variable, we made use of the 
Weibull distribution, a density commonly used for time-to-event data [69]. Our goal was 
to estimate the mean and median age of onset, along with their confidence intervals, to 
facilitate comparisons across the three genotypic groups.  
 Taking advantage of a Bayesian strategy, we assume yij ~ Weibull (r, 𝑒𝑒−𝑏𝑏𝑖𝑖), where 
yij is the observed age at diagnosis for the j-th (j = 1, 2, …, ni) dog in the i-th (i = 1,2, 
…,3) genotypic class and bi is the effect of the i-th genotypic class. With this 
representation of the scale (r) and shape (𝑒𝑒−𝑏𝑏𝑖𝑖) parameters of the Weibull density, the 
median of the i-th genotypic class is 𝑒𝑒−𝑏𝑏𝑖𝑖 log(2)1/r and the mean of the i-th genotypic 
class is 𝑒𝑒−𝑏𝑏𝑖𝑖 Γ(1 + 1/r).    
In addition, we assumed a prior density for the unknown genetic parameters (bi) 
to have a null mean and common variance σ (i.e., (bi ~ N(0, σ)). We consider the weakly 
informative prior for σ ~ Cauchy(0,25) [70]. For the scale parameter, r, we assume the 
weakly informative prior of r ~ exponential(0.001). The Monte Carlo Markov Chain 
(MCMC) sampling process was run in 4 chains through the public-domain software Stan 
[71], with each chain based on 50,000 total samples, and the first 20,000 were removed 
as part of the warm-up process, then thinned to every 20th sample, resulting in a MCMC 
sample of 6,000 values [71]. Convergence to the posterior density was evaluated by the 
Gelman-Rubin test statistic, where values less than 1.05 indicate that the MCMC 
sampling process was adequate to the data evaluated [72]. 
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Genetic interaction analyses.  
All affected (n=132) and healthy (n=390) dogs were used to investigate possible 
interactions between the PAN2 variant encoding p.Arg492Cys and MAP3K7CL 
c.383_392ACTCCACAAA>GACT in dogs homozygous for 002:01/009:01/001:01 vs. 
dogs heterozygous for the haplotype. Three-locus genotypes observed in fewer than five 
dogs were excluded. For a given disease state (cases vs. controls) and a given pair of 
genotypic classes i (i = A/A, A/a, or a/a) and j (j = B/B, B/b, or b/b), ncases ij ~ 
Binomial(ncases ij + ncontrols ij , pij) where ncases ij is the number of observed cases in the 
combination of the genotypic class of locus i and that of locus j,  ncontrols ij is the number 
of unaffected dogs in the combination of genotypic class of locus i and that of locus j.  
Finally, pij is the probability of disease for the combined genotypic classes of i and j.  
Estimation of the unknown elements of our model must ensure estimates of pij 
within the interval [0,1], recognizing that several genotypic classes have zero or few 
cases. We utilized a hierarchical Bayesian framework facilitated through the public-
domain software Stan [71] to address this problem [73]. Stan can be accessed through the 
public-domain language R [74]. Log-odds was used to estimate pij, i.e., log(pij /(1- pij)) = 
intercept + addAi + domAi+ addBj + domBj + add x addij + add x domij + dom x addij + 
dom x domij, where intercept represents a term common to all genotypic classes, addAi, 
addBj domAi and domBj represent the additive and dominance terms respectively for loci 
A and B, and add x addij + add x domij + dom x addij + dom x domij represent the four 
possible epistatic interaction terms for all possible additive and dominance combinations 
[53]. 
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We assumed a prior density for the intercept and unknown genetic parameters, 
with null mean and common variance σ (i.e., N(0, σ)). Subsequently, we consider the 
weakly informative prior for σ ~ Cauchy(0,25) [70]. We used the same MCMC 
parameters here as described above. 
 
Chromosome 12 selective sweeps.  
We identified all SNPs on chromosome 12 present in five collie genomes (3 cases 
and 2 controls) and used a creeping window size ≤1 Mb to identify runs of homozygosity 
[75]. Windows containing fewer than 50 SNPs were excluded and gaps >10kb between 
SNPs were ignored. The heterozygosity (Hp) statistic was calculated for all windows and 
Z-transformed, making the average Hp value equal to zero and the standard deviation 
equal to 1. The –ZHp distribution was plotted in R to show putatively selected regions 
greater than 3.4 standard deviations from the mean. 
 
PMEL  
D' between PMEL and PAN2 was calculated as a measure of LD using all dogs 
for which coat pattern phenotypes were available (112 cases, 385 controls). A total of 98 
dogs (10 cases and 88 controls) were described as merle-patterned, a semi-dominant trait 
caused by the Merle (M) allele of PMEL, and assumed to possess the Mm genotype. 
Computation of D', along with a test of significance from zero, was facilitated through 




SNP data are available in dbSNP under BioProject number PRJNA338128. All 
whole genome and transcriptome data generated for this study were deposited in SRA 
genomes under accesssion number SRP081080. Accession numbers for eight of the 27 
other breeds used in variant filtering are SRX1360633, SRX1360635, SRX1360637, 
SRX1360639, SRX1022256, SRX1022262, SRX1022286, and SRP081080. 
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 The outcome of this work was the identification of mutations underlying three 
inherited diseases of dogs: nemaline rod myopathy in American bulldogs, limb girdle 
muscular dystrophy in Boston terriers, and dermatomyositis in collies and Shetland 
sheepdogs. Genetic tests are now available to facilitate breeding decisions and reduce the 
risk of disease in the affected breeds. 
 
Nemaline rod myopathy in American bulldogs 
 Genome-wide SNP and whole-exome resequencing (WES) data were generated 
for a nuclear family of American bulldogs (ABDs) with two autosomal recessive cases of 
nemaline rod myopathy. Candidate intervals were determined based on allele frequency 
in the cases vs. the unaffected family members. SNP genotypes consistent with an 
autosomal recessive inheritance pattern were identified proximal to NEB and TNNT1, two 
known candidate genes. WES revealed a nonsense mutation in exon 176 of183 in NEB. 
This variant was absent in unrelated ABDs as well as dogs of other breeds, indicating that 
it is private to the family. A genetic test now exists for nemaline rod myopathy in ABDs, 
and this work demonstrated the utility of WES in detecting autosomal recessive variants 





Limb girdle muscular dystrophy in Boston terriers 
 We identified independent mutations in SGCD causing limb girdle muscular 
dystrophy (LGMD) in two unrelated Boston terriers. LGMD has been described 
previously in dogs but never molecularly characterized until now. WES of the cases and 
unaffected family members of one case revealed two SGCD deletions: a 2 bp deletion 
segregating in the family and a 19.4 kb deletion encompassing exons 7 and 8 of SGCD in 
the unrelated case. Given that LGMD is rare in dogs and that both affected dogs were of 
the same breed, we expected to identify a single mutation present at a very low frequency 
in the Boston terrier breed. This work again demonstrates the efficacy of WES for 
identifying causative mutations of simple recessive disorders, particularly when candidate 
genes are available. Should future cases of LGMD be identified in Boston terriers, a test 
is now available for each of the identified mutations, and there is now potential for a 
large animal model for LGMD2F gene therapy. 
 
Dermatomyositis in collies and Shetland sheepdogs 
 Dermatomyositis (DMS) is a complex autoimmune disease with environmental 
and genetic influences and is a model for human juvenile dermatomyositis (JDM). To 
date, major associations with JDM have not been identified outside of the major 
histocompatibility complex (MHC), although other risk factors of strong effect are 
believed to exist. Investigation of the dog leukocyte antigen loci in affected and healthy 
collies and Shetland sheepdogs revealed a haplotype overrepresented among affected 
dogs (DLA-DRB1*002:01/-DQA1*009:01/-DQB1*001:01). Through a combination of 
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genome-wide association studies (GWAS), whole genome resequencing (WGS), and 
transcriptome sequencing, we identified strong associations with variants in two genes 
never before implicated in disease, PAN2 and MAP3K7CL. Furthermore, we found 
evidence for additive-by-additive epistasis between the novel risk loci.  
 None of the risk alleles were private to collies and Shetland sheepdogs, but these 
breeds were unique in their high frequencies of risk alleles at the three loci. We 
determined that linkage disequilibrium between the M allele of SILV and the wildtype 
PAN2 allele has impeded elimination of the risk allele in the absence of a genetic test. 
Furthermore, we found evidence for a selective sweep including the MHC on 
chromosome 12 in collies, explaining their fixation for the DMS risk haplotype. It is 
likely that breeders fixed this locus inadvertently while selecting for a desirable 
phenotype. The presence of a second MHC haplotype in Shetland sheepdogs contributed 
to the higher incidence of the MAP3K7CL variant in this breed. 
 This work is the first in dogs to identify disease risk associated with combinations 
of polymorphisms across three independent loci, and we can explain 93% of cases with 
these three-locus genotypes. It has also yielded novel genes for investigation in human 
cases of dermatomyositis. Because DMS is fully penetrant in dogs homozygous for risk 
alleles at all three loci develop DMS, there is potential to study changes to the immune 
system prior to disease onset. Such research has not previously been possible and may 
allow for the development of biomarkers for diagnosis of JDM before clinical symptoms 
ensue.  
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For dogs, this work has resulted in a genetic test that will allow breeders to 
preserve genetic diversity, while reducing the incidence of the risk alleles in these breeds. 
Prior to the development of a test, affected dogs and parents of affected dogs would be 
culled from the breeding population. Now all dogs can be safely bred to produce puppies 
with low-risk genotypes, and Shetland sheepdog breeders can maintain the second DLA 
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Summary 
Exocrine pancreatic insufficiency is a digestive disorder resulting from 
insufficient secretion of enzymes from the pancreas. In dogs, this condition is often 
attributed to pancreatic acinar atrophy, wherein the enzyme-producing acinar cells are 
believed to be destroyed through an autoimmune process. Although exocrine pancreatic 
insufficiency affects many diverse breeds, to date, molecular studies have been limited to 
the German shepherd dog. A recent study of major histocompatibility genes in diseased 
and healthy German shepherd dogs identified both risk and protective haplotypes. Herein, 
we genotyped DLA-DQB1 in Pembroke Welsh corgis to determine if dog leukocyte 
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antigen alleles contribute to the pathogenesis of exocrine pancreatic insufficiency across 
dog breeds. We evaluated 14 affected and 43 control Pembroke Welsh corgis, which 
were selected based on an age of onset similar to German shepherd dogs. We identified 
one protective allele (odds ratio=0.13, P-value=0.044) and one risk allele (odds ratio=3.8, 
P-value=0.047). As in German shepherd dogs, the risk allele is a duplication of DLA-
DQB1 (alleles DQB1*013:03 and 017:01); however, Pembroke Welsh corgis have 
acquired a single polymorphism on DQB1*017:01. Thus, the DLA-DQB1 duplication is a 
risk allele for exocrine pancreatic insufficiency in at least two breeds. 
 
Exocrine pancreatic insufficiency (EPI) results from the failure of pancreatic 
acinar cells to produce enough enzymes for proper digestion of macromolecular nutrients. 
Clinical signs include increased appetite, weight loss, and loose stools. It has been 
suggested that clinical signs occur when <10% of pancreatic enzyme reserves remain [1]. 
EPI is typically managed with supplemental enzymes. Veterinarians screen for EPI 
through measurement of serum canine trypsin-like immunoreactivity (cTLI) 
concentration; however, the underlying cause is usually undetermined. In dogs, EPI is 
most commonly caused by pancreatic acinar atrophy (PAA), an autoimmune disorder 
resulting from selective degradation of acinar cells after lymphocytic infiltration [2]. 
PAA is responsible for hereditary forms of EPI and has a complex mode of inheritance 
[3].  
 EPI occurs across many dog breeds but is especially prevalent among German 
shepherd dogs (GSDs). Tsai et al. [4] recently identified associations between EPI and 
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four-locus dog leukocyte antigen (DLA) haplotypes in GSDs. The DLA locus is part of 
the canine major histocompatibility complex, a superlocus of genes involved in immune 
function. The identified risk haplotype (DLA-88*045:02/DLA-DRB1*012:01/DLA-
DQA1*004:01/DLA-DQB1*013:03+017:01; for nomenclature, see Kennedy et al. [5]) 
contains a DLA-DQB1 allele that is not found on other haplotypes. This allele is a 
duplication composed of two alleles (DQB1*013:03 and 017:01) and has been reported 
in at least 15 breeds [6], including several reported to have EPI. As in GSDs, Pembroke 
Welsh corgis (PWCs) have a young average age of onset (~3 years), which may imply a 
similar pathogenesis [7]. To determine whether DQB1*013:03+017:01 confers risk for 
development of EPI in breeds besides GSDs, we genotyped DLA-DQB1 in diseased and 
healthy PWCs. 
Whole blood or buccal cells were obtained from PWCs across 22 states recruited 
through www.epi4dogs.com and the Pembroke Welsh Corgi Club of America. All 
samples and informed owner consent were collected according to protocols approved by 
the Clemson University Institutional Review Board (IBC2008-17). Pedigree information 
was obtained for 54% of participants. Among these, all dogs were unrelated at the 
parental level with most unrelated through the grandparent level. All 14 PWC cases were 
diagnosed based on clinical assessment by their private veterinarians and fasting serum 
cTLI concentrations ≤2.5 µg/L (reference interval: 5.7-45 µg/L). PWC cases had an 
average age at diagnosis of 2.9 years.  
All 43 dogs selected as controls were ≥8 years of age (average=11 years), 
exhibited no clinical signs of EPI or digestive disorders, and had no immediate family 
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members diagnosed with EPI to the owner’s knowledge. Although rare, subclinical cases 
have been reported in GSDs [8]. Fasting serum samples were collected from six controls 
having the DLA-DQB1 duplication and submitted to the Gastrointestinal Laboratory at 
Texas A&M University for cTLI measurement. All dogs had cTLI concentrations within 
the normal range.   
 The hypervariable regions of DLA-DQB1 and DLA-DRB1 were amplified from 
genomic DNA using primers and thermal cycling parameters reported by Kennedy et al. 
[6] or modified from Massey et al. [9] (Table S1). Products were purified according to 
Massey et al. [9] and sequenced on an ABI 3730xl Genetic Analyzer (Life Technologies). 
Results were compared with published nucleotide sequences to assign genotypes [10], 
and statistical analyses were performed using VassarStats (Vassar College). 
 Gel extracted PCR product from a dog having a novel DLA-DQB1 allele was 
subcloned into pGEM®-T Easy vector according to the manufacturer’s protocols 
(Promega). Colonies containing the insert were selected, and the vector and insert were 
sequenced. 
In our cohort, we identified 11 DLA-DQB1 alleles, for which 96% of PWCs were 
heterozygous (Table 1). The most commonly observed alleles were DQB1*020:02 and 

















We initially genotyped seven cases and nine controls as heterozygous for 
DQB1*013:03+017:01. Eight of these were in combination with three alleles that did not 
match reported alleles but most closely resembled DQB1*001:01, 003:01, and 035:01. 
To better characterize these alleles, DLA-DRB1 genotypes were generated for five PWCs, 
representing each of the three unknown alleles. All dogs were heterozygous for 
DRB1*012:01, which is on a haplotype with DQB1*013:03+017:01 [11]. The alternate 
alleles were DRB1*002:01, 015:01, or 025:01, which are reported on the same 
haplotypes as DQB1*001:01, 003:01, and 035:01, respectively [11]. Further examination 
of DQB1 sequence data from all dogs having the duplication revealed a shared mutation 
DLA-DQB1 
Cases  Controls  OR 95% CI P-value 
n=14 (%)   n=43 (%)   
001:01 7 50  13 30  2.3 0.67–7.9 0.21 
002:01 2 14  13 30  0.38 0.075–1.97 0.31 
003:01 3 21  15 35  0.51 0.12–2.1 0.51 
007:01 0 0  1 2.3    - 
008:02 1 7.1  16 37  0.13 0.02–1.1 0.044 
013:02 0 0  1 2.3    - 
013:03 0 0  1 2.3    - 
013:03+ 
017:02 7 50  9 21  3.8 1.1–14 0.047 
020:02 6 43  15 35  1.4 0.41–4.8 0.75 
023:01 1 7.1  1 2.3    - 
035:01 0 0  1 2.3    - 
Table 1. Frequencies and statistical values for each DLA-DQB1 allele in PWC cases and 
controls under a dominant model. Statistical values are shown for alleles present in more than two 
PWCs and are calculated based on numbers of dogs with and without each allele. Significant values 
are highlighted in bold font. OR=odds ratio, CI=confidence interval 
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(c.236A>T) at a known polymorphic site. These data suggest that the mutation is present 
on the common allele, DQB1*013:03+017:01, rather than on the alternative alleles. 
Subcloning and sequencing of the DLA-DQB1 duplication revealed that the c.236A>T 
mutation is found in DQB1*017:01; no changes were present in DQB1*013:03 (Figure 
1A). The curator of the canine immunopolymorphism-MHC database termed the new 
allele DLA-DQB1*017:02 and the duplicated allele present in PWCs DLA-
DQB1*013:03+017:02. 
We subsequently developed a method of distinguishing dogs having 
DQB1*013:03+017:01 from those having DQB1*013:03+017:02 in direct sequences. 
Initially, c.236A>T was only apparent when the DLA-DQB1 duplication was paired with 
an allele having an A at this position (DQB1*001:01, 003:01, 023:01, and 035:01). 
Chromatograms from this allelic combination have a stronger A signal resulting from a 
2:1 ratio of As to Ts: one T from DQB1*017:02, one A from DQB1*013:03, and a 
second A from the third allele (Figure 1B). 
The remaining eight DQB1*013:03+017:01 alleles were paired with alleles 
having c.236A>T (DQB1*002:01, 008:02, and 020:02). Chromatograms from these 
allelic combinations showed a stronger T signal, suggesting a 1:2 ratio of As to Ts. In 
chromatograms from GSDs having DQB1*013:03+017:01 and an allele with c.236A>T, 
the A signal is greater (Figure 1B).  Therefore, we determined that the remaining PWCs 
have the DQB1*013:03+017:02 duplication, which is contributing the second T in the 
1:2 ratio, and that no dogs in our cohort have DQB1*013:03+017:01.  
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 To determine if DLA-DQB1 alleles are associated with EPI in PWCs, a Fisher’s 
exact test was conducted using numbers of dogs possessing a given allele. This approach 
assumes a dominant model, wherein only one allele is necessary to increase risk. 
DQB1*013:03+017:02 was determined to confer risk (OR=3.8, P-value=0.047). Another 
allele, DQB1*001:01, had an odds ratio suggestive of risk (OR>2.0), but its P-value was 
not significant (Table 1). 
A single allele, DQB1*008:02, was significantly associated with PWC controls, 
indicating protection. This allele was not observed in GSDs [4]. In GSDs, EPI-protective 
DLA haplotypes included DQB1 alleles 002:01 and 003:01 [4]. In the PWCs, these 
alleles had odds ratios suggestive of a protective effect (OR<0.5); however, the P-values 
were not significant (Table 1).  
In GSDs, the protective haplotype was dominant, such that the single dog having 
both protective and risk haplotypes did not develop EPI [4]. In this study, we observed 
two PWC controls that possessed both the risk and protective alleles. This genotype was 
not observed among PWC cases, indicating that the protective allele may be dominant to 
the risk allele. One case had DQB1*008:02 paired with a non-risk allele, suggesting that 
the protective allele does not fully prevent risk for EPI. 
 The duplication of DQB1*013:03 and 017:01 occurs across several breeds and 
represents an ancestral event. Genotyping of DLA-DRB1 showed that the PWC 
duplication occurs with DRB1*012:01, as does DQB1*013:03+017:01. Taken together, 
these data indicate that the duplication in PWCs is not a novel event. Rather, we suggest 
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that PWCs have acquired a polymorphism on DQB1*017:01 within the duplication, 
which has not yet been reported in other breeds. 
In conclusion, we have identified both risk and protective alleles contributing to 
EPI in PWCs. Our findings combined with those of Tsai et al. [4] show that this DLA-
DQB1 duplication is associated with EPI in multiple dog breeds. Further studies are 
necessary to determine if the duplication itself or a variant in linkage disequilibrium is 
contributing to the pathogenesis of EPI.  
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Reagents Temperature Time Cycles 
2X Reddy Mix 95°C 5 minutes 1 
Sterile water 95°C 30 seconds  0.4 μM Primer 73°C 1 minute 30 
50 ng DNA 72°C 1 minute   
 72°C 5 minutes 1 
Total reaction 
volume: 25 μL 4°C hold hold 
 







Supplemental information for Chapter 3 
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Supplemental information for Chapter 4 
 
S1 Figure. Clinical presentation of dermatomyositis. Canine dermatomyositis is a vasculopathy 
that initially manifests as cutaneous lesions across the bony prominences of the face, tail tip, limbs, 
and feet, shown here. Some dogs develop alopecia and more extensive lesions over time, resulting in 















S2 Figure. Manhattan and quantile-quantile plots of combined DMS GWAS (97 cases vs. 68 
controls). The -log10P-values (y-axis) for 98,520 Illumina SNPs are plotted against chromosome 
position (x-axis). The threshold for Bonferroni significance is shown as a black horizontal line. The 
P-value and position (canFam3) of the lead SNPs are reported. The Q-Q plot is boxed in purple and 






S3 Figure. MAP3K7CL indel with conservation and RUNX3 binding motif. UCSC 100 
Vertebrates track for human chr21:29,130,846-29,130,860 showing the G insertion and seven base 
pair deletion created by MAP3K7CL indel (Dog c.383_392ACTCCACAAA>GACT). Bases in gray 
differ from the dog reference sequence. The canine sequence is highlighted in yellow. The RUNX3 




S4 Figure. Three-locus genotype disease probabilities by sex. Probability of disease (y-axis) for all 
combinations of PAN2 (x-axis) and MAP3K7CL genotypes are plotted in dogs (73 affected and 145 
unaffected males; 59 affected and 245 unaffected females) (top) homozygous and (bottom) 







S5 Figure. Median age of onset for combinations of PAN2 and MAP3K7CL genotypes. Median 
age of onset is plotted for genotypes consisting of 2 (AAbb, aaBB, AaBb), 3 (AABb, AaBB), and 4 
(AABB) risk alleles at PAN2 and MAP3K7CL. CC and Cc genotypes were combined for analyses. 








S6 Figure. Collie selective sweeps on chromosome 12. ZH(p) values for all creeping windows 


























































S3 Table. Chromosome 31 variants segregating with the lead SNPs in the affected Shetland 
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